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ABSTRACT 
 
 Porcine circovirus type 2 (PCV2) is an emerging virus that may result in devastating 
disease that affects swine herds worldwide. Only a decade has passed since researchers began to 
study the characteristics of the virus and the resulting diseases, and limited information was 
available regarding the long term presence or persistence of the virus in healthy swine herds. Our 
research contributes to the knowledge of the persistence of the virus in serum and semen, and the 
PCV2 antibody profile in healthy pigs. In addition, we developed a novel quantitative 
polymerase chain reaction (PCR) assay and quantified the PCV2-shedding in healthy and PCVD 
(porcine circovirus disease)-affected pigs. Lastly, we determined the efficacy of a novel vaccine 
in a subset of pigs from a PCVD-affected herd.    
Porcine serum was assayed by two PCR protocols (nested polymerase chain reaction 
(nPCR) and non-nested PCR) and a competitive enzyme-linked immunosorbent assay (cELISA) 
to determine when PCV2 viremia and a rise in the serum level of PCV2-specific antibody (Ab) 
occurred in pigs raised in a large Canadian farrow-to-finish barn. Eight serial blood samples 
were collected from each of 40 pigs from 5 to 156 (±1.5) days of age; six pigs were removed 
from the study for various reasons at various times. Viremia was not detected in the samples 
collected before 72 days of age but was detected in those collected on or after 72 days: of 33 
pigs, seven (21%) had only one serum sample positive for PCV2 deoxyribonucleic acid (DNA) 
by nPCR after day 72; 11 (33%) were intermittently positive by nPCR, non-nested PCR, or both 
between 72 and 156 days; and the remaining 15 (45%) were repeatedly positive (in two to four 
samples). The level of serum Ab against PCV2 declined after weaning and increased between 72 
and 107 days of age, only after PCV2 was detected in serum. Our results show that PCV2 
viremia persists in the presence of elevated levels of PCV2-specific Ab. 
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In a separate study, we determined the long term presence or persistence of PCV2-
shedding in semen from healthy boars and the effects of PCV2 on sperm quality. A nPCR 
protocol was applied to porcine semen to demonstrate the PCV2-shedding patterns and duration 
in naturally-infected boars. Sperm morphology analysis was performed on a subset of samples to 
determine if the presence of PCV2 DNA in semen was associated with reduced semen quality. 
Semen was collected serially from 43 boars representing six breeds, aged 33.9 to 149.3 weeks. 
Of the 903 semen samples collected, 30 samples (3.3%) were positive for PCV2 DNA by nPCR 
from 13 boars. Boars shedding PCV2 DNA in semen ranged between 35.9 and 71.0 weeks of 
age, and shedding occurred over a period of up to 27.3 weeks. A semen nPCR test was 2.6 times 
more likely to be positive when collected from pigs that were ≤ 52 weeks of age and 3.0 times 
more likely to be positive when collected from pigs that were ≤26 w eeks from the time of entry 
into the stud main unit (Generalized Estimating Equations: P=0.02; 95% confidence interval (CI) 
of the Odd’s ratio (OR) 1.2 to 5.5 and P=0.01; 95% CI of the OR 1.3 to 6.9, respectively). PCV2 
DNA was detected in semen from Duroc and Landrace boars only; however, the semen of the 
Hamline, Large White maternal, Large White paternal, and Meishan-synthetic boars were 
negative for PCV2 DNA. These results demonstrate a sporadic and long-term shedding pattern of 
PCV2 DNA in semen from naturally-infected boars. PCV2 DNA in semen did not have 
detrimental effects on sperm morphology; however, boar age and possibly breed may contribute 
to the persistence of PCV2-shedding in semen.  
To further our studies of PCV2-shedding from pigs, a PCV2 quantitative molecular assay 
was developed using SYBR green technology. This assay allowed for the simultaneous 
quantification of all the genotypes of PCV2. The emergence of multiple genotypes of PCV2, as 
demonstrated by phylogenetic analysis of whole genome or capsid sequences, makes it necessary 
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to have quantitative diagnostic assays that perform equally well on all strains. The objectives of 
this study were to develop and validate a novel real-time PCR assay targeting the highly 
conserved replication-associated gene (Rep) open reading frame 1 (ORF1) and investigate the 
effects of diagnostic specimen choice on its performance. The assay was tested in naturally-
infected conventional pigs, experimentally-infected gnotobiotic pigs, and plasmid-spiked 
negative serum, lung tissue, and feces and found to have a linear detection range of 2.2 × 103 to 
2.2 × 1010 copies of PCV2 per mL. The assay successfully detected and quantified PCV2 DNA 
in serum, buffy coat, feces, and multiple lymphoid (bronchial, mesenteric, and superficial 
inguinal lymph nodes, thymus, tonsil, ileal Peyer’s patches, and spleen) and non-lymphoid 
(myocardium, lung, kidney, liver, and gluteal muscle) tissues from naturally-infected pigs. 
Across all tissues and sera of naturally-infected pigs, the mean PCV2 concentration was 3.0 logs 
higher in pigs that were demonstrating weight loss, as a primary clinical sign of PMWS 
(postweaning multisystemic wasting syndrome) when compared with PMWS-nonaffected pigs. 
PCV2 concentration measured by tissue culture and immunohistochemical staining in 
homogenized liver samples of experimentally-infected gnotobiotic pigs were compared to the 
concentrations estimated by quantitative PCR. Similar trends were noted with increasing PCV2 
concentration detected in subclinically-infected to severely PMWS-affected pigs across all 
assays. Our diagnostic assay was developed with a conserved target sequence, and performed 
efficiently in the quantification of PCV2 in a variety of tissues from naturally- and 
experimentally-infected pigs. 
With a quantitative assay, we then determined the amount of PCV2-shedding in feces 
between healthy and PCVD-affected herds. This study examined if pigs (n=100) in a PCVD-
affected herd shed more PCV2 in their feces than pigs in a PCVD-nonaffected herd (n=101), and 
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if differences in shedding among production stages within and between the herds existed. The 
PCV2-shedding was quantified by real-time PCR. The highest median PCV2-shedding was 
found in the nursery stage of the PCVD-affected herd and in the grower stage of the PCVD-
nonaffected herd. The PCV2-shedding was significantly higher in earlier stages (newly weaned, 
nursery, and pregrower) in the PCVD-affected herd (Wilcoxon Rank Sum; P<0.001) compared 
with the PCVD-nonaffected herd. PCV2 DNA was not detected in a significant proportion of 
lactating sows (parity ≥3) in the PCVD -nonaffected herd (Fisher’s Exact Test; P=0.001) 
compared with the PCVD-affected herd. The results of this study suggest there may be an 
association between the presence of PCV2 in the feces of lactating sows and increased PCV2-
shedding in younger pigs. 
The quantitative PCR assay was used in a field study to determine the efficacy of a novel 
transdermal immune stimulating complex (ISCOM) technology-based PCV2 virus-like particle 
(VLP) vaccine candidate administered at one and three weeks of age. Fifty-four pigs (vaccinates 
(VX) (n=27); non-vaccinated controls (CTRL) (n=27)) with variable levels of maternally-
derived antibodies (MDAb) (high (hiMDAb) versus low (loMDAb)) in a PCVD-affected farm 
were assessed for PCV2-specific Ab levels by cELISA, PCV2 DNA concentration in serum and 
feces by quantitative PCR, mortality, and average daily gain (ADG) from 1 to 18 weeks of age. 
A significant reduction in mortality (P=0.05) was observed in the VX. PCV2 DNA concentration 
in serum was lower in the VX at 9 and 11 weeks of age (P=0.003 and 0.01, respectively). The 
VX (both hiMDAb and loMDAb groups) at nine weeks of age had a higher Ab response to 
natural PCV2 exposure, while the CTRL (both hiMDAb and loMDAb groups) had a 
significantly reduced Ab response in comparison. This suggests a priming of the immune 
response against PCV2 infection by use of the vaccine. During this period from 9 to 11 weeks of 
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age, the loMDAb CTRL were susceptible to PCVD. PCV2-specific Ab in serum was 
significantly higher in the VX at the onset of PCVD-related mortality (P=0.001); however, no 
significant difference was observed in the PCV2 DNA concentration shed in feces, or in ADG 
between VX and CTRL. The benefit of the novel ISCOM vaccine was most evident in the 
loMDAb VX, as these pigs were protected from a PCVD-related death that was otherwise 
experienced in the loMDAb CTRL. However, producers and veterinarians using a vaccine 
against PCV2 would expect a significant improvement in ADG and reduced viral shedding in 
feces. Although the vaccine prevented a PCVD-related death in the highest risk population, the 
loMDAb group, modifications regarding the protein or ISCOM concentration, or PCV2 protein 
construction should be considered to potentially improve the vaccine’s efficacy. This study is the 
first report of the use of an ISCOM matrix (Matrix Q) mixed with PCV2 VLP protein 
administered transdermally for the prevention of PCVD in swine. 
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CHAPTER 1 
 
 
LITERATURE REVIEW 
 
 
1.1 Introduction 
 
 We are fortunate to have at the University of Saskatchewan two pioneers in the discovery 
and research of porcine circovirus type 2 (PCV2) and porcine circovirus disease (PCVD). The 
practising veterinarian, Dr. John Harding, who assisted in the recognition and description of the 
first reported PCV2-associated disease named postweaning multisystemic wasting syndrome 
(PMWS) (89) and Dr. John Ellis, the researcher that lead a group to discover the novel virus 
associated with the severe wasting disease in pigs (59). Drs. Harding and Ellis have continued to 
research this emerging virus and the plethora of diseases associated with it. The body of research 
and publications which study PCV2 has grown substantially over the last 10 years; however, the 
morbidity and mortality related to PCV2 infection in pigs continues to plague the swine industry.  
A resurgence of severe PCVD was recognized in Eastern Canada after the industry 
believed the worst was over (35), but this only proved that there is more to learn and understand 
regarding the virus. Vaccines against PCV2 are now available and are efficacious, but 
researchers continue to study and uncover complex revelations about the virus and its associated 
diseases. 
This thesis is concerned with the development and use of molecular assays for studies 
that contribute to the knowledge in multiple areas of PCV2 research. Four of the five research 
articles (chapters three to six) that comprise this thesis have been peer-reviewed and published. 
The fifth manuscript (chapter seven) has been submitted for publication. Our research began in 
the year 2002 and many basic questions were not known about the virus prior to this year and 
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include: are healthy infected pigs persistently infected; what is the PCV2-specific antibody (Ab) 
status of healthy infected pigs over time; is PCV2 shed in semen from healthy boars; and does 
the presence of PCV2 affect semen quality? After our research began, real-time quantitative 
polymerase chain reaction (PCR) technology became widely available and we subsequently 
developed a novel PCV2 real-time assay. This novel assay enabled us to determine what amount 
of virus is shed in feces between healthy and PCVD-affected pigs, and among production stages. 
Additionally, as a contributing member to a European consortium research group with objectives 
to investigate various aspects of PCV2 and PCVD, we tested the efficacy of a novel vaccine in 
PCVD-affected pigs using the real-time assay.  
Most of the questions we sought answers to were driven by the industry and producers 
that are working diligently to make whatever changes possible to reduce their pig losses, 
improve production, and to prevent PCVD from affecting their herds. Our research answered 
many questions previously unanswered and contributes to the basic understanding of PCV2 
epidemiology in pig populations.   
1.2 Discovery of Porcine Circovirus 
 Porcine circovirus (PCV) was first detected in 1974 by Tischer and others as a 
papovavirus- and picornavirus-like contaminant of a continuous porcine kidney cell line, PK15 
(ATCC-CCL31) (215). In 1982, this newly isolated virus was further characterized and reported 
to be a persistent noncytopathic, noneveloped virus with a capsid size of 17 nm (214). By 
serologic study, this noncytopathic PCV was found to be present in pig populations, but did not 
appear to be associated with any clinical disease or pathology (216). It was not realized until 15 
years later that another PCV had emerged and was associated with a severe wasting disease in 
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pigs in Canada. This devastating disease was termed postweaning multisystemic wasting 
syndrome (PMWS) (47;89). 
1.2.1 Postweaning Multisystemic Wasting Syndrome 
 PMWS was recognized as a widespread disease by 1997 to 1998; however, retrospective 
data based on necropsies dating back to the early 1990’s confirmed that the disease had resulted 
in pig losses in one farm in 1991 (89). Dr. JCS Harding, a practising veterinarian from 
Humboldt, Saskatchewan, and Dr. EG Clark, a pathologist at the Western College of Veterinary 
Medicine together described the clinical and pathological disease that was emerging in Canadian 
swine (47;88). Affected pigs were primarily 7 to 15 weeks of age and presented with wasting, 
respiratory distress, enlarged lymph nodes, diarrhea, pallor, and jaundice (89). Subsequently, 
these wasted pigs were found to have gross and/or microscopic lesions in multiple organs and 
suffered from an array of potential pathologies. Granulomatous interstitial pneumonia, hepatitis, 
nephritis, myocarditis, enteritis, pancreatitis, and lymphadenopathy were some of the lesions 
recognized in pigs suffering with PMWS (11;59).  
1.2.2 PCV2 Isolation 
 In 1998, a PCV was found to be associated with PMWS in affected pigs in 
Saskatchewan, Alberta, and Manitoba (59). The virus was recognized in lesions from multiple 
organs using electron microscopy, immunohistochemical staining (IHC), and in situ 
hybridization (ISH). This was the first report that described a PCV associated with clinical 
disease and pathology in pigs. Additionally, it was recognized that the PCV associated with 
PMWS was closely related to, but antigenically distinct from the PCV tissue culture contaminant 
that was discovered in 1974 (11). This observation lead to the terminology (152) of porcine 
circovirus type 1 (PCV1) to describe the nonpathogenic circovirus first described by Tischer and 
 3
others in 1974 (215), and porcine circovirus type 2 (PCV2) to describe the circovirus associated 
with PMWS in young pigs by Ellis and others (59).  
Genomic analysis confirmed that two distinct types of PCV existed, as the approximate 
sequence identity of the genome between PCV1 and PCV2 was 68% (85). A more 
comprehensive analysis revealed that the sequence identity among PCV2 isolated from North 
American and European outbreaks of PMWS was >96% similar, and these PCV2 isolates had 
<82% sequence identity with PCV1 (152).   
1.2.3 PCV2 Classification 
 The family Circoviridae includes two genera: Circovirus and Gyrovirus. This family of 
viruses contains small, nonenveloped icosahedral viruses with a circular single stranded DNA 
genome (214). Within the Circovirus genus, many viruses are represented and host species 
infected include: birds, plants, and mammals (20;218). The most studied virus within the 
Circovirus genus is PCV2; however, the Circovirus genus consists of more than 10 pathogenic 
and nonpathogenic viruses (150;217;219). The Gyrovirus genus includes a single virus named 
the chicken anaemia virus (48). Recently, in the 2009 Virus Taxonomy List (224), the 
Anellovirus genus was removed from the Circoviridae family and reclassified as the 
Anelloviridae family and consists of the torque teno viruses found to infect people and mammals 
(96). 
1.2.4 PCV2 Structure and Molecular Characteristics 
 With a virion size of approximately 17 nm and a genome of 1.7 kb, PCV is the smallest 
virus known to replicate autonomously (150;214). The genome is a single stranded covalently 
closed circle and replicates via rolling circle replication (39). This replication mechanism 
involves an intermediate double stranded replicative form of DNA (150). The origin of 
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replication (ORI) of PCV2 is found adjacent to a stem loop structure (Figure 1.1) which contains 
a conserved nonamer sequence at the apex and a palindrome of 11 nucleotides producing the 
stem (143).  
The virus contains three expressed open reading frames (ORF) which encode a 
replication-associated protein Rep (ORF1), a capsid protein Cap (ORF2), and a viral-induced 
apoptotic protein (ORF3). An ambisense orientation of the Rep and Cap genes is observed where 
ORF1 is located immediately following the ORI and a short intergenic region, and ORF2 is 
located immediately preceding a short intergenic region and the stem loop structure. 
The Rep gene produces both a full-length transcript from the viral plus or positive strand 
(Rep: 314 aa) and a truncated form (Rep’: 178 aa) and both are necessary for the initiation of 
replication of the virus (66). The Cap gene transcribes the structural capsid protein (233 aa) in a 
counter clockwise direction from the minus or negative strand, and is the main antigenic 
determinant of the virus (141). The recently described ORF3 protein (105 aa) is transcribed from 
the ORF1 region; however, it is transcribed in a counter clockwise direction and is not required 
for viral replication, but is hypothesized to contribute to apoptotic activity and viral pathogenesis 
(125). 
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Figure 1.1: PCV2 genomic organization of ORF1 (replication-associated protein; Rep), 
ORF2 (capsid protein; Cap), and ORF3 (apoptotic protein). Origin of replication (ORI) is located 
adjacent to the stem loop structure and precedes ORF1. Ambisense orientation is observed 
between ORF1 and ORF2, where ORF3 is contained within ORF1 and in a counter clockwise 
direction. Nucleotide base pair designations for 1, 500, 1000, and 1500 are noted. 
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1.2.5 PCV2 Virulence and Genotypes 
 It was recognized shortly after the isolation of PCV2 from PMWS-affected pigs that 
PCV2 isolates were divergent and comprised genotypes (142). Universal nomenclature to 
describe the genotypes of PCV2 was proposed in 2008 (202) and PCV2a, PCV2b, and PCV2c 
are now used by PCV2 researchers in the published literature. Recombination among PCV 
isolates has been described (40;49;95;122;130); therefore, further designations, such as 
PCV1/2a, will arise to describe the recombined virus based on the nucleotide sequences of the 
Rep and Cap genes of the virus (72).      
      It wasn’t until 2005 when a Canadian report described increased PCVD and PCVD-
related mortality associated with a genotype of PCV2 that speculation regarding variable 
virulence among PCV2 genotypes began (36). A PCR-restriction fragment length polymorphism 
(RFLP) assay found that PCV2 banding type 321, analogous to PCV2b, a novel genotype to 
swine in Ontario and Quebec, was associated with the outbreak (35). 
Several PCV2 differential molecular diagnostic assays have been reported and include: 
PCR-RFLP (35), nested PCR (nPCR) (129), non-nested PCR (95), SYBR green real-time 
quantitative PCR (148;230), and a probe multiplex real-time quantitative PCR (70). Although it 
is agreed that genotypes of PCV2 exist, primarily described as PCV2a and PCV2b (77), the 
evidence to support variable virulence among PCV2 isolates is contradictory. There is currently 
no consensus regarding the association between PCV2 genotype and virulence, as reports both 
support (71;77;118;174;213) and refute (13;50;144;179) the association. 
Lesions of unprecedented severity were found to be associated with genotype PCV2b and 
a resurgence of PCVD in Canada in field studies (35;71); however, specific pathogen-free pigs 
infected experimentally with PCV2a or PCV2b had no significant differences in lymphoid 
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lesions, but significant differences were found between isolates within the same genotype (179). 
Among the recent controversy regarding the potential variability in PCV2 virulence and its 
association with PCV2 genotype, one study has emerged in germ-free swine that considers the 
dual or heterologous infection with PCV2a and/or PCV2b, and the order of infection (i.e. 2a/2a, 
2b;2b, 2a/2b, and 2b/2a) (92). It was found that dual heterologous infection with PCV2a given 
first, followed by PCV2b seven days later, or vice versa, induced severe clinical PCVD. Due to 
the ubiquitous nature of PCV2 in swine populations around the globe and the presence of both 
PCV2a and PCV2b within populations (77), clarifying the controversy regarding PCV2 
genotypes and their relationship to increased or decreased virulence will be difficult in field 
studies.    
1.3 Porcine Circovirus Disease 
PCVD (5;199) and porcine circovirus-associated disease (PCVAD) (17) are terms that 
have been presented to describe the gamut of clinical disease outcomes associated with PCV2 
infection. PMWS was the first described clinical syndrome associated with PCV2 infection (59); 
however, it has been determined that the virus contributes to several other syndromes, disorders, 
or clinical outcomes.  
1.3.1 Spectrum of Diseases 
Since the recognition of PMWS in the 1990’s (89), PCV2 has been associated with 
additional disease syndromes including: congenital tremors (CT) (211), fetal myocarditis (28) 
porcine respiratory disease complex (PRDC) (105), porcine dermatitis and nephropathy 
syndrome (PDNS) (8), proliferating and necrotizing pneumonia (PNP) (79), abortion (228), and 
other reproductive disorders (166). Recently, central nervous system lesions in slaughter-weight 
pigs has been described associated with PCV2 infection (55). 
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Conflicting reports have been published regarding the association between PCV2 
infection and CT (82;103;211). CT is associated with demyelination of the brain and spinal cord, 
and type A2 specifically refers to a viral cause of the disease (38). One study found no PCV2 in 
the central nervous system of piglets suffering from CT using ISH and IHC labeling on paraffin-
embedded tissues (103), whilst another study found that piglets affected with CT had more PCV-
infected cells in the brain and spinal cord than clinically normal piglets using ISH, PCR, and 
indirect immunofluorescence antibody (IFA) testing on frozen tissue sections (211). Since PCV2 
has not been definitively proven or disproven to be associated with CT and is sporadically 
observed, it is not considered a significant outcome of PCV2 infection. 
PRDC is associated with PCV2 infection (105), but the disease has a multifactorial 
etiology (86). PRDC is characterized by lung lesions, where bronchopneumonia and interstitial 
pneumonia are often present alone or in combination (86). Vaccination against PCV2 infection 
can reduce mortality and improve production parameters due to PRDC (86). This observation 
further supports the hypothesis that PCV2 infection contributes to the manifestation of PRDC. 
PDNS primarily affects older pigs and is associated with red to purple lesions on the skin 
and kidneys accompanied by necrotizing vasculitis, and may be exacerbated by coinfections such 
as porcine reproductive and respiratory syndrome virus (PRRSV) with PCV2 (8;41). However, it 
was recently reported that combined experimental infection with torque teno virus genogroup 1 
and PRRSV, in the absence of PCV2 infection, produced disease similar to PDNS (116). Further 
study to reveal the specific cause or factors required to produce PDNS are needed.    
PCV2 was the most commonly found pathogen in PNP cases in a retrospective study 
using ISH (79). PRRSV, swine influenza virus, and Aujeszky’s disease virus are also found 
associated with PNP which causes a severe form of interstitial pneumonia. However, it is 
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accepted that PCV2 may be the main contributor to PNP in Europe and that PRRSV may further 
manifest PNP in North America (79). 
Reproductive failure as a result of PCV2 infection was recognized shortly after the 
discovery of PCV2 (151). An increase in abortion (25;228), premature delivery (184), 
mummified fetuses (190), fetal myocarditis (28;228), and the delivery of stillborn piglets 
(10;109) have been observed in association with the detection of PCV2 antigen and/or nucleic 
acid in tissues or sera of affected piglets. 
1.3.2 Cofactors Contributing to Disease 
 Both infectious and noninfectious cofactors may contribute to the development of PCVD 
in swine. Activation of the immune system appears to be a critical component of the 
pathogenesis of PCV2 infection in swine that exhibit PMWS (12;114). Gnotobiotic piglets 
infected experimentally with PCV2 produced only mild asymptomatic disease; however, 
injection with keyhole limpet hemocyanin in incomplete Freund’s adjuvant after PCV2 infection 
resulted in clinical disease (114). Vaccination may also activate the immune system and 
perpetuate the progression of PMWS, as seen in experimental infection with PCV2 followed by 
vaccination with a commercial Mycoplasma hyopneumoniae vaccine (113). A modified-live 
PRRSV vaccine increased PCV2 replication and microscopic lesions in PCV2 infected swine 
(6). Additionally, the time of vaccination in relation to the time of PCV2 infection may also 
affect the outcome and severity of lesions in PCVD-affected pigs (172). 
 The immune status of the sow, specifically the amount of PCV2 antibody (Ab) and PCV2 
virus circulating in maternal serum may affect piglet susceptibility to PCVD. Maternally-derived 
PCV2 Ab passively transferred in colostrum may protect piglets and is Ab titre-dependent (149). 
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Additionally, PCV2 viremia in sows was significantly related to mortality in PCVD-affected 
piglets (31). 
Numerous studies have determined that experimental coinfection with other swine 
pathogens exacerbates PCVD. The severe symptoms associated with PMWS do not manifest 
when PCV2 is inoculated alone experimentally; however, PCV2 coinfection with PRRSV (10), 
porcine parvovirus (PPV)  (7;61), or M. hyopneumoniae (181) results in disease.   
 Intensified production practices have been implicated as a cofactor in the development of 
PCVD. Early weaning practices or relocating piglets prior to 21 days of age (193) and other 
considerations including pen size, cross-fostering, and vaccination protocols are risk factors for 
the development of PCVD (194). It has been hypothesized that geographic areas with PCV2 
positive swine that have not progressed to PCVD have more traditional production practices and 
have not conformed to more intensified animal husbandry (132).  
 Breed differences in the susceptibility to PCVD have been observed where less mortality 
is experienced in those pigs of pure or cross-bred Pietrain decent compared with Large White 
and Duroc crossed pigs (127), and where Landrace are most susceptible when compared with 
Pietrain, Large White and Duroc bred pigs (171;178). Recently, specific genes have been 
identified and associated with an increased susceptibility to PCVD (101). 
1.3.3 Prevalence and Geography 
 PCV2 infection and PCVD have been reported in swine populations worldwide: USA 
(11;64), Canada (59), Great Britain (80), Ireland (210), Europe (14;142), Japan (170), Korea 
(106), Philippines (139), China (130), South Africa (54), Mexico (220), France (194), New 
Zealand (162), Australia (167), and Brazil (37). The effect of PCVD in swine populations is 
variable based on published data. However, morbidity commonly ranges from 4% to 30% of 
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PCVD-affected pigs but can escalate to 60%, and the mortality among affected pigs can reach 
50% (64) to 80% (201). 
1.4 Transmission 
 PCV2 is shed in various secretions including: oronasal (200;207), urine, feces (147), 
colostrum (206), milk (81), and semen (146). The primary route of PCV2 transmission is 
theorized to be the oronasal route. An increase in the amount of PCV2 shed in secretions 
(147;200) and found in tissues (91) is observed in pigs with more severe PCVD when compared 
with less severe or asymptomatic disease. PCV2 may also be transmitted from the sow to the 
fetus via in utero infection. Additionally, it has been hypothesized that plasma infected with 
PCV2 used in commercial feed may infect naïve pigs with PCV2; however, contradictory studies 
both support (185) and refute (205) this hypothesis. 
1.4.1 Horizontal Transmission 
 Oronasal infection with PCV2 occurs via contact with contaminated urine and feces 
(199), and direct nose-to-nose contact with PCV2-infected pigs (26;138). Under experimental 
conditions, PCV2 negative pigs are infected when allowed contact with PCV2 positive pigs 
(4;26) and PCV2 negative pigs can develop PCVD by mingling with PCVD-affected pigs (168). 
Additionally, PCVD can be transmitted to healthy PCV2 positive pigs when allowed to mingle 
with PCVD-affected pigs (56;117). Aerosol transmission of PCV2 is possible, as concentrations 
of airborne PCV2 of up to 107 copies of PCV2 per cubic metre of air were detected by 
quantitative PCR (222). PCVD can also be transmitted from affected to unaffected PCV2 
positive pigs in an adjacent pen or across an aisle without direct contact between the pens; 
however, direct contact results in higher numbers of PCVD-affected pigs  (117). 
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1.4.2 Vertical Transmission 
Vertical transmission from the pregnant sow to her unborn piglets was demonstrated in 
experimental infection studies where the pregnant sow was infected with PCV2 via the oronasal 
route (83;184). Additionally, PCV2 has been detected in stillborn or aborted fetuses in 
reproductive failure studies (25;140;228). Experimental transuterine infection with PCV2 into 
the peritoneal cavity of fetuses results in infection of untreated fetuses in the uterus (188;197). 
Oronasal infection is considered the primary route of infection with PCV2, and historically, 
vertical transmission appeared to be relatively rare (140). However, a recent study detected 
PCV2 DNA in the pre-suckle serum of 39.9% of neonatal pigs (204); therefore, vertical 
transmission from the pregnant sow to her fetuses may be a greater risk for PCV2 transmission 
than originally reported. 
1.4.3 PCV2 Shed in Semen 
 
 Experimental infection (119;136) and field studies (146;198) have shown that PCV2 is 
shed in semen. Typically, PCV2 detection studies in semen are based on molecular methods and 
the infectivity of the virus is not known. It is argued that remnants of the virus or viral DNA may 
be present, but that infectious virus is not present. Intraperitoneal injection of PCV2 positive raw 
semen does result in viremia in naïve pigs confirming the potential infectivity of PCV2 in semen; 
however, artificial insemination did not result in viremia or seroconversion of inseminated naïve 
females in the same study (137). Semen spiked with PCV2 can infect naïve females when 
introduced by artificial insemination; therefore, it is not known at this time if PCV2 in naturally-
infected semen is sufficient to infect naïve females (135). Additionally, in experimental studies, 
semen spiked with PCV2 and artificially-inseminated into sows has resulted in both the infection 
of the sow and of her piglets (134). 
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Several studies are contradictory in regards to PCV2 and its presence in semen. PCV2 
was not found to be shed persistently or intermittently in semen in an experimental infection 
study (136); however, PCV2 was shed intermittently in semen samples from naturally-infected 
boars up to 71 weeks of age (146). In addition, contradictory results were found regarding the 
fractionation of semen and the presence of PCV2 in the various subfractions. PCV2 was more 
abundant in the seminal fluid and nonsperm cell fraction in one study (108), and in the cellular or 
sperm fraction in a different study (183). Recently, it has been shown that vaccination against 
PCV2 decreases the duration of PCV2 viral shedding in semen (3).  
1.5 PCV2 Diagnostics 
 A multitude of assays exist to detect either PCV2 DNA or antigen, or PCV2-specific Ab 
in serum of live or dead infected pigs. However, the detection of PCV2 does not assume PCVD. 
Unthriftiness of young pigs aged 7 to 15 weeks of age is the most outstanding clinical sign of 
PMWS and gross and/or microscopic lesions in multiple organs during post mortem examination 
suggests PCV2-associated disease; however, additional histopathological findings are necessary 
to definitively diagnose PMWS and PCVD. 
1.5.1 Individual and Herd Differential Diagnosis 
 A case definition for a PMWS diagnosis was proposed in 2000 by Sorden (209) and in 
2007, the American Association of Swine Veterinarians (AASV) Board of Directors approved a 
case definition with the minimum findings necessary to diagnose PCVD (17). These 
histopathological findings include: depletion of lymphoid cells in lymphoid tissues; disseminated 
granulomatous inflammation in one or more tissues; detection of PCV2 within the lesions; and in 
the case of PCVD in reproductive disease, PCV2 antigen should be present in fetal myocarditis 
lesions. 
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 Two diagnostic criteria have been proposed for PCVD diagnosis at the herd level. Firstly, 
a significant increase in the post-weaning mortality and wasting is observed, and secondly, the 
diagnosis of PCVD based on the individual case definition should occur in a minimum of 20% of 
pigs during post-mortem examination (76).   
1.5.2 PCR Assays 
 The PCR detection of PCV2 has been used since early in the characterization of the virus 
and its disease outcomes, as early as 1998 (152). PCR assays have evolved from conventional 
nested (104;119) and non-nested assays (32;152) to real-time quantitative assays 
(97;148;183;230). A multiplex real-time quantitative assay is also available to differentiate 
between genotypes PCV2a and PCV2b of the virus (71).  
PCR assays have been used in all types of tissues and excretions from PCV2-infected 
pigs (119;148;200) and may have applications in the diagnosis of PCVD at the herd level (76). 
Quantification of PCV2 in tissues (91) is correlated with the severity of lesions and distinguishes 
wasting from non-wasting pigs. Additionally, a threshold quantitative PCR used on serum or 
swabs has been proposed as a diagnostic test in live animals suspected of PCVD to confirm the 
diagnosis (169;200). However, it should be considered that not all PCR assays are equivalent. An 
inter-laboratory ring trial determined that significant variability in the quantification and 
detection limit of PCV2 is present across assays (90). 
1.5.3 PCV2 Antibody Detection Assays 
 Various quantitative and semi-quantitative assays have been applied to pig sera to 
measure the PCV2-specific Ab present. Assays for Ab detection include: ELISA techniques 
(24;124;225); IFA techniques (10;232); serum neutralization assay (67;154); and the 
immunoperoxidase monolayer assay (IPMA) (59). Additionally, an enzyme-linked 
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immunosorbent assay (ELISA) has been developed to differentiate between genotypes PCV2a 
and PCV2b of the virus (186) and assays exist to differentiate among immunoglobulins (Ig) IgG 
(225), IgM (33;153;227), and IgA (153) Ab.  
PCV2-specific Ab are prevalent in swine herds worldwide and in both the presence and 
absence of PCVD (15;58;126;145;191;192;225). This observation is consistent with the 
widespread infection, often subclinically, of PCV2 in pigs. Contradictory studies show that Ab 
levels may be higher in herds affected with PCVD (191;208), or may be comparable to healthy 
or unaffected herds (121). Similar to PCR assays, it must be considered that Ab detection assays 
vary in their ability to quantify PCV2-specific Ab levels in serum accurately. 
1.6 PCVD Prevention and Control 
 Considering the relative novelty of PCV2, several commercial vaccines became available 
in less than 10 years from the time of discovery of the virus (59). Until the availability of 
vaccines, control and prevention of PCVD were based on the modification of production 
practices. The intensification of swine husbandry has been hypothesized to exacerbate PCVD 
and Dr. Francois Madec presented a 20-point plan that brought humanity, biosecurity, and 
hygiene back to the practice of raising pigs (131). The 20-point plan is a guide for proper herd 
management and many of the points, if not followed, have been proven as risk factors for PCVD 
(133;193;194). Additionally, research has confirmed that controlling concomitant infections 
reduces PCVD, as PPV (7) and PRRSV (10) contribute to the development of PCVD and the 
replication of PCV2. 
1.6.1 Swine Production Practices: ‘Madec’s 20-point Plan’ 
 
 Madec’s 20-point plan (131) reduces and prevents the development of PCVD in PCV2-
positive herds. The 20-point plan could be applied to other pathogenic infections that may affect 
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a herd, as its focus is on the management of the herd. There are actions to perform affecting 
multiple production stages, with the focal point on strict “all-in all-out” procedures where 
cleaning and disinfection of areas occurs between batches of pigs. Other points of the plan 
include: small farrowing pens with solid dividers; treatment of sows against parasites prior to 
farrowing; limited adoptions; suitable animal density in pens; good air quality; suitable room 
temperature; avoid mixing batches, pens, and animals from different barns; suitable vaccine 
program; strict hygiene; and the separation of sick animals from the healthy. The implementation 
of the proper production practices described in the 20-point plan are reported to improve the dire 
situation in herds affected with PCVD (133;199).   
1.6.2 PCV2 Vaccination 
 There are currently four commercial vaccines available for the prevention of PCVD 
around the world. Not all of the vaccines are equally available, as licensing and registration vary 
among countries. In April of 2010, Suvaxyn® PCV2 One Dose was removed voluntarily from the 
marketplace. It is hypothesized that a recombined PCV1/2a emerged from vaccination with the 
chimeric killed vaccine strain (72). As of May 2011, the Suvaxyn® PCV2 One Dose vaccine has 
not been reintroduced to the marketplace.  
Two approaches to produce protective immunity against PCV2 exist among the 
commercial vaccines and include: (1) vaccination of the sow to passively transfer immunity to 
the neonate; or (2) vaccination of the piglet at or near the period of time when weaning occurs. 
Details regarding the manufacturer, type of antigen, and approach of the vaccines are outlined in 
Table 1.1 (76).  
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Vaccine Manufacturer Antigen Licensed for 
Circovac® Merial Inactivated PCV2 Females 
Ingelvac Circoflex® Boehringer Ingelheim PCV2 ORF2 protein Piglets >2 weeks
Suvaxyn® PCV2 One Dose Fort Dodge Pfizer Inactivated PCV1-2 chimera Piglets >4 weeks
Porcillis® PCV(EU) 
Circumvent® PCV (US) 
Intervet-Schering PCV2 ORF2 protein Piglets >3 weeks
 
Table 1.1: Details of commercial vaccines produced against PCV2 (76). 
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Vaccination of sows increases serum PCV2-specific Ab that is then delivered passively to 
the neonatal suckling piglet. Passive immunity has been found to be protective against PCVD 
(100) and reduces serum viral load (177). In the piglet, maternally-derived Ab begin to wane 
between three and six weeks of age (145); therefore, vaccination can be effective in eliciting an 
immune response in the piglet to protect against PCVD. This protective response reduces the 
morbidity and mortality associated with PCVD during the late nursery and into the finisher 
period (7 weeks of age and older) (110;203). Piglet vaccination protects against PCV2 viremia, 
fecal and nasal shedding (68), and the development of microscopic lymphoid lesions (176). All 
vaccines are effective in improving various outcomes of PCV2 infection and disease in both 
experimental and field conditions. Reduced mortality and/or PCVD-related morbidity 
(63;100;110;203), reduced PCV2-associated lymphoid lesions (173;203), reduced incidence or 
prevalence of coinfections (110), and improved average daily gain (63;98;187) are accomplished 
by use of commercial PCV2 vaccines. 
Maternally-derived Ab specific to PCV2 may interfere with the priming of piglets by 
vaccination and this is reflected in the published PCV2 vaccine research. Conflicting studies 
reveal that maternally-derived Ab may (69) or may not (68;110;175) affect vaccine efficacy. 
1.6.3 Immune Stimulating Complex 
 First described in 1984, an immune stimulating complex (ISCOM) matrix consists of 
purified saponins extracted from the tree bark of Quillaja saponaria Molina, then mixed with 
detergent solubilized cholesterol, and followed by dialysis and ultrafiltration to yield a matrix or 
adjuvant (158). A stable structure is formed by the addition of a desired antigen and results in 
both a delivery system and an innate immune stimulant or adjuvant for the antigen (128). The 
advantages of applying ISCOMs in vaccination are numerous. ISCOM vaccine preparations are 
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immune modulators which overcome obstacles observed with the use of conventional (killed or 
non-replicating) vaccines including: route of administration (160), type of immune response 
elicited (161), and the ability to prime the animal in the presence of maternally or passively-
derived Ab (156;159;161).   
ISCOMs elicit a more balanced Th1/Th2 or cell-mediated/Ab type response than that 
observed with typical killed or inactived vaccines (155). ISCOMs have the ability to induce 
responses that will provide protection against intracellular pathogens by the production of strong 
T cell responses and enhanced cytokine secretion (18;46). An additional advantage of ISCOMs is 
that modified-live (attenuated) organisms or adjuvants with toxic or pathological sequellae are 
not necessary. The ISCOM matrix provides the delivery system and the adjuvant activity 
necessary to produce a protective and balanced immune response with the use of killed antigens, 
mimicking the response observed in natural infection but not typically seen with the use of killed 
or inactived vaccines.  
The ability of vaccines to prime the host’s immune system in the presence of maternal or 
passively-derived Ab is currently one of the greatest challenges of vaccine development. 
Experimental ISCOM vaccines can prime the host’s immune system in the presence of maternal 
Ab (84;157) and experimental vaccines have been tested in multiple animal species for bacteria, 
viruses, and parasites (1;2;21;22;30;34;164). ISCOMs are currently being used in clinical trial 
studies for humans and commercial vaccines including an equine influenza vaccine (27) and a 
feline leukemia virus vaccine (226) are available in veterinary medicine.   
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CHAPTER 2 
 
 
HYPOTHESES AND SPECIFIC OBJECTIVES 
 
 
 Five distinct studies or manuscripts comprise this thesis (chapters three to seven). The 
hypotheses tested in chapters three, four, six, and seven were based on PCV2 infection in 
naturally-infected pigs and the use of molecular diagnostic tests to detect or quantify PCV2. 
Each chapter represents an individual study and all studies were performed in different 
commercial swine facilities located in Saskatchewan.  
Our research was possible due to the collaboration of local commercial swine facilities 
with an interest in the prevention or reduction of PCVD in their swine herds. All facilities 
observed high biosecurity procedures and had management and production practices consistent 
with reducing the risk and impact of PCVD. None of the facilities used commercial or 
experimental PCV2 vaccines, with the exception of our study to determine the efficacy of a 
novel ISCOM PCV2-VLP vaccine.  
Chapter five, describing the development and validation of a novel quantitative PCR 
assay, allowed us to complete the studies in chapters six and seven. The samples used in the 
validation of the assay for chapter five were from archived tissues stored by Dr. Steve Krakowka 
at the Ohio State University (tissue samples from pigs experimentally-infected with PCV2 and 
non-infected gnotobiotic pigs) and Dr. John Harding at the University of Saskatchewan (tissue 
samples from PCV2 naturally-infected conventional pigs). 
 The hypotheses tested are listed in order of the chapters presented in this thesis.  
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Hypothesis 1: 
PCV2 is detected persistently in the serum of naturally-infected healthy pigs and the 
virus persists in the presence of high levels of PCV2-specific IgG Ab. 
Objectives: 
(1) To test pig serum by two PCR protocols (nested and non-nested conventional PCR) 
across all production stages (farrowing crate, nursery, grower area, and finisher area) at 5, 12, 19, 
40, 72, 107, 135, and 156 days of age for the presence of PCV2 DNA in each of 40 pigs.  
(2) To test pig serum by cELISA across all production stages (farrowing crate, nursery, 
grower area, and finisher area) at 5, 12, 19, 40, 72, 107, 135, and 156 days of age for the level of 
PCV2-specific Ab in each of 40 pigs. 
(3) To determine when PCV2 DNA is detected in young healthy pigs that are infected 
naturally with PCV2. 
(4) To determine when PCV2-specific maternally-derived Ab in serum begins to wane 
and the pigs’ adaptive IgG Ab response increases following natural infection with PCV2. 
(5) To determine if significant relationships exist among measures of serum IgG Ab, 
viremia, and the effects of sex, breed, or age. 
Hypothesis 2: 
PCV2 is shed intermittently in boar semen over many months and the virus does not 
have detrimental effects on semen quality in healthy boars infected naturally with PCV2. 
Objectives: 
(1) To test semen over a nine month period by conventional nested PCR for the presence 
of PCV2 DNA from 43 healthy boars infected naturally with PCV2. 
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(2) To test semen quality by sperm morphological analysis to determine if the presence of 
PCV2 in semen affects the quality. 
(3) To determine the relationship among boar age, time after stud entry, breed, and a 
semen sample positive with PCV2 DNA. 
Hypothesis 3: 
A quantitative SYBR green real-time PCR assay can be developed and used to 
quantify PCV2 in tissues from pigs infected naturally and experimentally with PCV2. 
Objectives: 
(1) To develop a novel SYBR green quantitative PCR that targets the highly conserved 
Rep gene (ORF1) of PCV2. 
 (2) To test the novel assay in multiple tissues from pigs infected naturally with PCV2. 
Tissues to include: serum, buffy coat, feces, and multiple lymphoid (bronchial, mesenteric, and 
superficial inguinal lymph nodes, thymus, tonsil, ileal Peyer’s patches, and spleen) and non-
lymphoid (myocardium, lung, kidney, liver, and gluteal muscle) tissues. 
 (3) To validate the developed PCR using tissues from conventional pigs infected 
naturally with PCV2, gnotobiotic pigs infected experimentally with PCV2, and plasmid-spiked 
negative serum, lung, and fecal samples. 
 (4) To determine the effects of tissue specimen on the performance of the novel PCR 
assay using samples spiked with PCV2 DNA. 
 (5) To compare PCV2 concentrations measured by tissue culture and 
immunohistochemical staining in homogenized liver samples of gnotobiotic pigs infected 
experimentally with PCV2 with the DNA concentrations estimated by the novel PCR assay. 
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Hypothesis 4: 
Young pigs (<16 weeks of age) in a PCVD-affected commercial herd shed 
significantly more PCV2 DNA in their feces compared with pigs in a nonaffected herd. 
Objectives: 
(1) To use the quantitative PCR assay developed in hypothesis three to test 100 pooled 
fecal samples. “Pooled” refers to multiple samples collected from the floor of a single pen which 
are subsequently combined into one larger sample or “pool”. Ten pooled samples will be 
collected from age-matched pigs in each of a PCVD-affected and a nonaffected herd and across 
all production stages (newly weaned, nursery, pregrower, grower, finisher, virgin gilt, bred gilt, 
lactating sow parity ≤2, lactating sow ≥3, and boar). 
(2) To determine which production stage or stages of PCVD-affected and nonaffected 
pigs have significantly higher amounts of PCV2 DNA shed in feces. 
(3) To determine if PCV2 DNA shed in feces is significantly different between stages in 
a PCVD-affected and a nonaffected herd. 
(4) To determine if a higher amount of PCV2 DNA shed in sow feces may result in a 
higher amount of PCV2 DNA shed in the feces of young pigs.    
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Hypothesis 5: 
A novel transdermal ISCOM technology-based PCV2 VLP vaccine administered at 
one and three weeks of age does not produce adverse reactions, significantly reduces 
mortality and the PCV2 DNA concentration in serum and feces, and significantly increases 
the PCV2 specific IgG Ab and the average daily gain in a naturally-PCVD-affected herd. 
Objectives: 
(1) To determine if rectal temperature, injection site reactivity, and the activity level of 
one week old conventional piglets are adversely affected by varied doses of ISCOM Matrix Q 
injected subcutaneously. 
(2) To vaccinate 54 pigs (vaccinates (n=27); non-vaccinated controls (n=27)) with a 
novel ISCOM technology based PCV2 VLP vaccine at one and three weeks of age. 
(3) To collect blood samples from 54 pigs at 1, 3, 7, 9, 11, 13, and 18 weeks of age and 
rectal fecal samples at 3, 7, 9, 11, 13, and 18 weeks of age. Using these samples, test three non-
invasive outcome measures to determine the efficacy of the novel vaccine including: PCV2-
specific IgG Ab level in serum and PCV2 DNA concentration in serum and feces. 
(4) To weigh pigs at 1 and 18 weeks of age to determine the average daily gain (ADG) of 
each pig. 
(5) To determine if the novel vaccine administered transdermally could successfully 
prime young pigs against PCV2 in the presence of PCV2 maternally-derived Ab and reduce the 
mortality caused by PCVD. 
(6) To determine if the amount of maternally-derived IgG Ab (high or low based on a 
median cutoff value) in serum at one week of age has an affect on the development of the PCV2-
specific IgG Ab response of pigs in a PCVD-affected herd. 
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CHAPTER 3 
 
DETECTION OF PCV2 VIREMIA AND SEROCONVERSION IN NATURALLY 
INFECTED PIGS IN A FARROW-TO-FINISH BARN 
Can J Vet Res. 2006. McIntosh KA, Harding JCS, Ellis JA, Appleyard GD. 
 
This research was conducted in 2002-2003. 
 
 
3.1 Abstract 
 
Porcine serum was assayed by two PCR protocols (nested PCR (nPCR) and non-nested 
PCR) and a cELISA assay to determine when PCV2 viremia and a rise in the serum level of 
PCV2-specific Ab occurred in pigs raised in a large Canadian farrow-to-finish barn. Eight serial 
blood samples were collected from each of 40 pigs from 5 to 156 (±1.5) days of age; six pigs 
were removed from the study for various reasons and at various times. Viremia was not detected 
in the samples collected before 72 days of age but was detected in those collected on or after 72 
days: of 33 pigs, seven (21%) had only one serum sample positive for PCV2 DNA by nPCR after 
day 72; 11 (33%) were intermittently positive by nPCR, non-nested PCR, or both between 72 
and 156 days; and the remaining 15 (45%) were repeatedly positive (in two to four samples). The 
level of serum Ab against PCV2 declined after weaning and increased between 72 and 107 days 
of age, only after PCV2 was detected in serum. Our results show that PCV2 viremia persists in 
the presence of elevated levels of PCV2-specific Ab. 
3.2 Introduction 
PCV was identified in 1974 as a picornavirus-like contaminant of a porcine kidney tissue 
culture cell line (PK15) (215). In 1998, an antigenically and genetically distinct PCV (152) was 
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isolated from pig tissue and named PCV type 2 (PCV2) (59); PCV2 is associated with clinical 
disease in pigs (102;151).  
PMWS, an emerging disease in swine, is caused by PCV2 (59;60;102). However, 
evidence suggests that manifestation requires coinfection with a pathogen such as porcine 
parvovirus (PPV) (61) or a similar immune stimulant (114), stress, or cofactor. This syndrome, 
first described in 1996 (89), debilitates swine 7 to 15 weeks of age, with wasting, respiratory 
distress, enlarged lymph nodes, diarrhea, pallor, and jaundice. Gross and histologic lesions affect 
multiple organ systems and are associated with interstitial pneumonia, lymphadenopathy, 
hepatitis, nephritis, myocarditis, enteritis, and pancreatitis (11;47).  
Ab specific for PCV2 have been retrospectively detected in swine serum dating back to 
1973 (225). Diagnosis of PMWS relies on the detection of either PCV2-specific nucleic acid or 
antigen associated with lesions in affected tissues. The virus has been isolated from heart, lung, 
liver, kidney, spleen, salivary gland, lymph node, thyroid, thymus, gastrointestinal tract, feces, 
pancreas, testes, and brain (60;102). 
The primary route of transmission is unknown, but evidence suggests that PCV2 can be 
transmitted both horizontally and vertically. It has been detected in ocular, nasal, and fecal 
samples from naturally infected swine (207). Isolation of PCV2 from aborted pig fetal tissue 
(151) suggests vertical transmission. Detection of PCV2 nucleic acid in the semen of naturally 
(107) and experimentally (120) infected boars suggests transmission from boars to PCV2-naïve 
gilts and their litters. 
Although PMWS is the most commonly recognized disease associated with PCV2, the 
virus has been implicated in additional diseases, such as congenital tremors (CT) (211), porcine 
dermatitis and nephropathy syndrome (PDNS), and reproductive disorders (151). 
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It is hypothesized that swine industry intensification, management and weaning practices, 
and infectious triggering agents (such as PPV) may have contributed to the emergence of PCV2-
associated diseases in swine, as a retrospective serologic study determined that PCV2 has been 
present in swine populations for 30 years (225). 
There has been limited investigation into the spread of PCV2 in breeding herds in which 
the virus is endemic but the incidence of overt disease is low. We examined the dynamics of 
PCV2 Ab production in relation to virus circulation within the farm. Epidemiologic studies will 
contribute to the development of vaccination strategies and understanding of the pathogenesis of 
PCV2 and PCV2-associated diseases. 
3.3 Materials and Methods 
3.3.1 Animals and Sample Collection 
Forty newborn pigs were randomly chosen at a high-security farrow-to-finish barn in 
Saskatchewan that housed 14 000 pigs. All 1200 sows in the barn had received vaccine against 
Erysipelothrix rhusiopathiae (Eryshield; Grand Laboratories, Larchwood, IA, USA), PPV 
(Parvo-Vac; Pfizer, Kirkland, QC, Canada), and Escherichia coli (Kolivax; Wyeth, Guelph, ON, 
Canada), and all pigs were routinely vaccinated at eight weeks of age against E. rhusiopathiae 
(Suvaxyn E-Oral; Wyeth, Markham, ON, Canada). 
The chosen pigs were not segregated from other animals in the barn but were ear-tagged 
to allow for relocation. They were either nursed by their biologic dam or fostered by cohort sows 
that had farrowed the same day; the piglets were arranged in farrowing crates separated by solid 
partitions from birth and until weaning at 19 days of age, as was routine in the barn. After 
weaning, the pigs were moved into the nursery until about 72 days of age, into grower areas until 
about 135 days of age, and then into finisher areas until slaughter at about 156 days of age. This 
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management practice, to relocate pigs to different sections of the barn at different growth stages, 
resulted in the mixing and remixing of pigs. Eight serum samples were serially collected from 
each of the pigs from the first week after birth and until slaughter, before movement into a new 
area, and at the midpoint of each stage (Figure 3.1) between October 2002 and March 2003. A 
minimum of 3 mL of blood was collected from the anterior vena cava into individual sterile 
serum tubes, transported in a chilled, insulated box, and stored at 4°C for 18 hours before sample 
preparation. 
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Figure 3.1:  Schematic, based on the relocation of pigs within a Saskatchewan farrow-
to-finish barn, of the collection of eight blood samples from 40 pigs between October 
2002 and March 2003 to determine the percent inhibition (PI) of antibody specific for 
porcine circovirus type 2 (PCV2) by competitive enzyme-linked immunosorbent assay 
(cELISA) and to detect PCV2 DNA by nested (n) or non-nested polymerase chain 
reaction (PCR) at the following stages and average ages (±1.5 days): postpartum (5 
days), mid-farrowing (12 days), weaning (19 days), mid-nursery (40 days), end of 
nursery (72 days), mid-grower (107 days), end of grower (135 days), and slaughter (156 
days). Collections were made before relocation. 
a average age ±1.5 days of pigs at each blood collection 
b blood collections made prior to relocation  
 
    b  
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Animals entering the facility were not screened for PCV2-specific Ab or PCV2 in blood 
or tissues, but the only live animals accepted as replacement stock were those delivered by 
cesarean section or hysterectomy. Artificial insemination was performed with the use of semen 
from boars that had been serologically found to be PCV2-positive (unpublished data, 2003) by a 
cELISA (225). The barn had experienced sporadic cases of PMWS and other PCV2-associated 
syndromes since 1999 but had no significant losses due to PCV2-related diseases. Diagnosis of 
suspected PMWS was based on observed jaundice, unthriftiness, and dyspnea, and was 
confirmed by histopathologic and immunohistochemical study of tissues. Blood samples were 
centrifuged at 500 × g for 15 minutes at 4ºC. Serum was removed and stored in sterile 1.5 mL 
microcentrifuge tubes at -70ºC until DNA extraction and PCR or cELISA analysis. 
3.3.2 DNA Extraction 
For DNA extraction, from 200 µL of each serum sample, a commercial kit (DNeasy 
Tissue Kit; Qiagen, Mississauga, ON, Canada) was used according to the manufacturer’s 
instructions, except that the DNA was recovered with the use of 100 µL of sterile water. The 
DNA was stored at -70°C for 24 hours before PCR. All extractions were tested in duplicate by 
each PCR protocol in a commercial amplification system (PTC-200 DNA Engine; MJ Research, 
Watertown, MA, USA).  
3.3.3 PCR Assays 
Two previously described PCR protocols (61;119) were adapted to reduce nonspecific 
amplification and improve the detection of PCV2 in serum. For nPCR (119), the reaction-mix 
concentrations were adjusted to 1.6 µM of each primer and 1.25 U of Taq DNA polymerase 
(Fermentas Taq DNA polymerase; VWR International, Edmonton, AB, Canada); for non-nested 
PCR (61) the annealing temperature was adjusted to 58°C. 
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The lowest detection limit of each PCR assay, expressed as the median tissue culture 
infective dose (TCID50/mL), was determined with the use of 10-fold dilutions of PCV2 field 
isolate Stoon7 (59) spiked into 200 µL aliquots of serum known to be PCV2-negative and DNA 
extracted as described above. The Stoon7 had been obtained from porcine lymph tissue in 1998 
from a PMWS case in Saskatchewan; the concentration of PCV2 in tissue culture was 
determined by a previously described immunoperoxidase monolayer assay (59) after one passage 
in PCV-negative PK15 cells. The lowest detection limits of the nPCR and non-nested PCR 
assays were 9.7 × 10-4 and 9.7 × 10-2 TCID50/mL, respectively. 
3.3.4 Competitive ELISA Assay 
A previously described cELISA (225) was used to detect PCV2-specific Ab in porcine 
serum with the following adaptations: plates were coated with partially purified PCV2 (225) 
(French isolate 48285) recovered from a pig with PMWS in 1998 (11) and diluted to achieve a 
well concentration of 0.2 µg; goat immunoglobulin against mouse antigen, labeled with 
horseradish peroxidase and containing 4% normal goat serum, was diluted to 1:5000; and the 
enzyme substrate was incubated for 20 minutes. Percent inhibition (PI) values greater than 44% 
were considered positive for PCV2-specific Ab on the basis of previously published data (225). 
3.3.5 Statistical Analysis 
The SAS GENMOD procedure (94) was used to analyze factors influencing Ab PI or 
persistence of viremia in the tested pigs. Univariate analyses were performed to investigate the 
possibility of a relationship between the measured variables and breed, sex, or age at the 
beginning of the experiment. The model used was Y = µ + sexi or breedj or + days of agek where 
Y = an observed value for Ab PI or viremia; µ = the population mean for that trait; sexi = a fixed 
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effect due to sex, where i = 1 or 2; breedj = a fixed effect due to breeding line, where j = l, h, or 
w; and days of agek = a fixed effect of age on the first bleeding-day group, where k = 3, 4, 5, 
6, or 7. Partial data sets were included in this analysis because the procedure accounts for 
missing values. 
3.4 Results 
3.4.1 Animals 
The piglets used in this study were farrowed between October 3rd and 7th, 2002, and 
varied by sex (23 males, 17 females) and breed (26 Large White, 10 Landrace, and four 
Hamline). The first blood collection was made at 5 ± 1.5 (range three to seven) days of age. Six 
pigs were removed at various times from the study because of missing ear tags (three pigs), 
chronic lameness (two pigs), and congenital heart disease (one pig). 
3.4.2 PCR and Competitive ELISA Assays 
As Figure 3.2 shows, the PI of PCV2-specific Ab declined after weaning, and viremia 
was subsequently detected by nPCR and non-nested PCR. The PI of PCV2-specific Ab rose after 
the viremia (between 72 and 107 days of age) and remained elevated until the end of the study. 
The nPCR assay detected PCV2 DNA in more serum samples than did the PCR assay. Of 34 
pigs tested, seven (21%) had only one serum sample positive for PCV2 DNA by nPCR after day 
72, 11 (33%) were intermittently positive by nPCR, non-nested PCR, or both between 72 and 
156 days, and the remaining 15 (45%) were repeatedly positive (in two to four samples). 
 
 
 
 
 33
  
0 50 100 150 200
0
25
50
75
100
125
PCR
nPCR
0
25
50
75
100
PCV2 antibody
Time (days of age)
P
er
ce
nt
 In
hi
bi
ti
on
Percent P
C
R
 positive
 
Figure 3.2: Changes in mean percent inhibition (PI) of porcine circovirus type 2 (PCV2) 
specific antibody (black squares) according to competitive enzyme-linked immunosorbent assay 
(cELISA); PI values above 44% were considered positive for diagnostic purposes. A rise in 
PCV2 DNA, an indicator of serum viremia, determined from replicate serum samples, was 
detected by nPCR (grey triangles) or non-nested polymerase chain reaction (PCR) (white 
triangles) after a decline in serum antibody PI. 
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3.4.3 Statistical Analysis 
There were no significant correlations between measures of serum Ab or viremia and 
effects of sex, breed, or age. The pigs in this study belonged to a herd that was endemically 
infected with PCV2 and since 1999 had experienced occasional confirmed cases of PMWS or 
PCV2-associated diseases. They were not segregated but were maintained in the barn with the 
remaining population and relocated to pens according to previously established management 
practices. There were no recognized cases of PMWS or PCV2-associated diseases during the 
blood collection period (October 2002 to March 2003) among the study pigs. 
3.5 Discussion 
To compare PI levels of PCV2-specific serum Ab between pigs and over time, cELISA 
was used. The piglets had high PIs from the time of first measurement, 5 (±1.5) days after birth 
and until weaning at 19 days of age, which indicated transfer of maternal Ab to nursing piglets. 
A further decline in PI was observed at 40 and 72 days of age, the lowest level being observed at 
72 days (53 days after weaning), coincident with PCR detection of viremia. The average PI for 
any collection was above the cutoff for a positive result. However, 10% and 15% of the pigs 
tested at 40 and 72 days of age, respectively, had PIs below 44%, which suggests wide variation 
in serum Ab levels among animals. Variation was greater before viremia, owing to passive Ab 
absorption: the decay of maternally-derived Ab may vary between two weeks and several 
months (221;223), and maternal Ab may be only partially protective against viral diseases in 
swine (51). The effect of sow immunity or colostrum on the variation in piglet antibody levels 
was not investigated in this study but needs to be elucidated.  
Viremia was not detected until 72 days of age, which suggests either sufficient protection 
by maternal PCV2-specific Ab or another immunocellular mechanism before 72 days or the 
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absence of exposure to infectious PCV2. Since PCV2 was present and has circulated within the 
population used for this study, it is possible that the pigs had been exposed to the virus before 72 
days of age. The fact that PCV2 can be detected in ocular, nasal, and fecal samples from 
naturally infected swine (207) supports the transmission of virus from sows to nursing piglets 
and between littermates or penmates, or both. It has been postulated that vertical transmission of 
PCV2 can occur in fetal pigs, as the virus has been isolated from tissues of aborted and stillborn 
animals (151). Infectious PCV2 transmission via semen or colostrum has not been reported but is 
a possible means of transmission to fetal or nursing piglets. However, the spread of PCV2 to 
naïve pigs may be greatest during the mixing and remixing of pigs in the nursery (at 40 to 72 
days of age), coincident with declining serum levels of PCV2-specific maternal Ab (Figure 3.2). 
The level of PCV2-specific Ab increased after 72 days of age and remained high until the 
end of the study. The sequence of events suggests that PCV2 viremia is established concurrently 
with waning Ab levels; however, PCV2 DNA was periodically detected in serum until the time 
of slaughter in the presence of high levels of Ab, which suggests that the Ab may be non-
neutralizing once an infection is established. 
The intermittent detection of PCV2 viremia may represent a real phenomenon, but it must 
be considered to be a possible function of the use of PCR as a method to detect PCV2 DNA in 
serum as an indicator of viremia. Although PCR is a sensitive molecular diagnostic tool that can 
detect PCV2 at low concentrations in serum, it does not provide information on quantity of virus 
or infective capability. The PCR assays used in this study had different detection limits. As 
expected, more samples were positive for PCV2 DNA in serum with the nPCR protocol than 
with the non-nested protocol. 
 36
Diseases associated with PCV2 have a significant impact on swine populations 
worldwide. Epidemiologic research on herds with endemic infection and either sporadic cases or 
a low incidence of overt PCV2-related disease has been limited. This report describes the 
relationship between PCV2 viremia and PCV2-specific serum Ab formation in pigs housed in a 
large farrow-to-finish barn in which PCV2 was endemic. Epidemiologic studies of PCV2 
infection in this type of pig management facility contribute to the development of vaccination 
strategies and understanding of the pathogenesis of PMWS and PCV2-associated diseases. The 
results from this study suggest that PCV2-specific Ab in serum is not sufficient to prevent or 
resolve PCV2 viremia in pigs. Furthermore, vaccination may be hindered by the presence of 
maternally derived PCV2-specific Ab in young pigs. 
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CHAPTER 4 
 
NESTED PCR DETECTION AND DURATION OF PCV2 IN SEMEN WITH SPERM 
MORPHOLOGICAL ANALYSIS FROM NATURALLY INFECTED BOARS 
J Vet Diagn Invest. 2006. McIntosh KA, Harding JCS, Parker SE, Ellis JA, Appleyard GD. 
This research was conducted in 2002-2003. 
 
 
4.1 Abstract 
A nPCR protocol was applied to porcine semen to demonstrate the PCV2-shedding 
patterns and duration in naturally infected boars. Sperm morphology analysis was performed on 
a subset of samples to determine if the presence of PCV2 DNA in semen was associated with 
reduced semen quality. Semen was collected serially from 43 boars representing six breeds, aged 
33.9 to 149.3 weeks. Of the 903 semen samples collected, 30 samples (3.3%) were positive for 
PCV2 DNA by nPCR from 13 boars. Boars shedding PCV2 DNA in semen ranged between 35.9 
and 71.0 weeks of age, and shedding occurred during a period of up to 27.3 weeks. A semen 
nPCR test was 2.6 times more likely to be positive when collected from pigs that were ≤52 
weeks of age, and 3.0 times more likely to be positive when collected from pigs that were ≤26 
weeks from time of entry into the stud main unit (generalized estimating equations: P=0.02; 95% 
confidence interval (CI) of the odds ratio (OR) 1.2 to 5.5, and P=0.01; 95% CI of the OR 1.3 to 
6.9, respectively). These results demonstrate a sporadic and long-term shedding pattern of PCV2 
DNA in semen from naturally infected boars. PCV2 DNA in semen does not appear to have 
detrimental effects on sperm morphology; however, boar age and, possibly, breed may contribute 
to the persistence of PCV2-shedding in semen. 
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4.2 Introduction 
PCV2 was first isolated in 1998 from swine exhibiting PMWS (59). PMWS was reported 
in 1996 and primarily affects swine 7 to 15 weeks of age with clinical features that include 
wasting, dyspnea, enlarged lymph nodes, diarrhea, pallor, and jaundice (88). Pathologically, 
PMWS is associated with gross and histological lesions in multiple organs, interstitial 
pneumonia, lymphadenopathy, hepatitis, nephritis, myocarditis, enteritis, and pancreatitis 
(11;59;88). 
Since the recognition of PCV2 as the etiological agent of PMWS (59;60;102), the virus 
has been associated with several porcine circoviral diseases (PCVD) in pigs: porcine dermatitis 
and nephropathy syndrome (PDNS) (151), congenital tremors (CT) (211), abortion, and 
reproductive failure (166). In experimental infections, PCV2 is detected in lesions from various 
tissues including heart, lung, spleen, liver, kidney, lymph node, thymus, thyroid, salivary gland, 
testes, intestine, pancreas, and brain (60;102).  
Although the pathogenesis and primary mode of transmission of PCV2 are not known, 
there is evidence to support horizontal and vertical transmission. PCV2 was detected in ocular, 
nasal, and fecal secretions from swine infected experimentally (115) and field cases (207) 
suggesting horizontal transmission. Recently, PCV2 has been cultured from the feces of swine 
infected naturally suggesting a potential for fecal–oral transmission (229). Evidence of vertical 
transmission is supported by the isolation of PCV2 from aborted fetal pig tissues (151) and 
stillbirth myocardia (166). PCV2 has been detected in semen from boars infected naturally with 
the virus, but the shedding pattern and duration were not determined (108). In another study, 
PCV2 DNA was detected intermittently in semen from day 5 to 47 postinfection in specific-
pathogen–free boars infected intranasally with PCV2 (119). There is, however, a lack of 
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information on the long-term shedding patterns of PCV2 in semen from naturally-infected boars. 
Because artificial insemination is a common practice in swine breeding, these data have 
significant implications for PCV2 transmission and biosecurity in the industry. Superior animal 
production and semen quality are required to be competitive and profitable, and it is unknown 
whether the presence of PCV2 in semen is detrimental to semen quality. In this study, the 
dynamics of PCV2-shedding in naturally-infected boars maintained in a commercial artificial 
insemination stud were measured and sperm morphological traits of PCV2-shedding and non-
shedding boar were characterized. 
4.3 Materials and Methods 
4.3.1 Animals and Sample Collection 
One-hundred-twenty-five boars, consisting of Duroc, Landrace, Hamline, Large White 
maternal, Large White paternal, and Meishan-synthetic breeds, were maintained at a biosecure 
commercial artificial insemination stud in Saskatchewan, Canada, permitted for export sales by 
the Canadian Food Inspection Agency. Semiannual vaccination for porcine parvovirus (Parvo-
vac; Pfizer Inc., Kirkland, QC, Canada) was maintained, and all boars entering the stud were 
quarantined for 50–60 days and treated with two doses of 25 mg/kg dihydrostreptomycin 
(Ethamycin; Pfizer Inc., Kirkland, QC, Canada) while in quarantine. Although the stud received 
replacement boars from both porcine respiratory and reproductive virus (PRRSV) positive and 
negative herds, there was no evidence of viral circulation in the stud based on quarterly serum 
(IgG) PRRSV ELISA (HerdChek ELISA; IDEXX Laboratories Inc., Westbrook, ME, USA) 
testing and weekly PCR (Prairie Diagnostic Services; University of Saskatchewan, Saskatoon, 
SK, Canada) testing of semen dating back to September 1999. Boars in this study were tested for 
PCV2 Ab in serum (to confirm exposure) by a cELISA, as previously described (225). During 
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this study, less than 5% of semen samples collected were unacceptable because of motility or 
morphological defects, and a conception rate of 88% was observed. 
4.3.2 DNA Extraction 
Semen collected from individual boars was diluted with extender (Androhep PLUS 
Extender; Minitube, Verona, WI, USA) to a final concentration of three-billion live sperm cells 
per 80 mL total volume, stored at 4ºC, and shipped in insulated boxes within 24 hours of 
collection from February 2002 to September 2003. Because semen collection was dictated by 
commercial product demand, collections from individual boars were subject to temporal 
variation. Extended semen was mixed by inversion, transferred to individual sterile 50 mL tubes, 
centrifuged at 500 × g at 4ºC for 15 minutes and supernatant gently poured off, leaving 5 mL of 
concentrated cells in residual extender. Samples were vortexed for 15 seconds, and 1 mL was 
transferred to individual sterile 1.5 mL microcentrifuge tubes and stored at -70ºC pending DNA 
extraction. DNA was extracted from 100 mL of each thawed and vortexed sample using a 
commercial kit (DNeasy tissue kit; Qiagen Inc., Mississauga, ON, Canada) according to the 
manufacturer’s instructions, except DNA was recovered with 100 mL of sterile water. DNA was 
stored at -70ºC for 24 hours pending nPCR. 
4.3.3 Nested PCR Assay 
A previously described nPCR protocol (119) was adapted to eliminate nonspecific 
amplification. Adaptations for the primary reaction included 1.0 mM MgCl2, 1.6 mM each 
primer, and 1.25 U Taq DNA polymerase (Fermentas Taq DNA polymerase; VWR International, 
Edmonton, AB, Canada) using the conditions of 94ºC for 3 minutes, followed by 20 cycles of 
94ºC for 1 minute, 65ºC for 1 minute, and 72ºC for 1 minute and 1 final cycle of 72ºC for 7 
minutes. Secondary reaction adaptations included 1.25 mM MgCl2, 1.6 mM each primer, and 
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1.25 U Taq DNA polymerase using the conditions of 94ºC for 3 minutes, followed by 35 cycles 
of 94ºC for 30 seconds, 65ºC for 30 seconds, and 72ºC for 30 seconds and one final cycle of 
72ºC for 7 minutes. Single DNA extractions were tested in duplicate by nPCR in a commercial 
amplification system (DNA Engine (PTC-200); MJ Research Inc., Watertown, MA, USA). If 
agreement between duplicates was not observed, DNA extraction and duplicate nPCR was 
repeated for that sample; all duplicate samples had agreement after re-extraction, when 
additional testing was necessary. Assay controls included extraction of a negative (100 mL 
sterile water) and a PCV2 virus–spiked sample using a PCV2 field isolate (Stoon7) at a 
concentration of 9.7 × 10-2 TCID50/mL in 100 mL of boar semen per extraction event. Stoon7 
was obtained from porcine lymph tissue in 1998 from a PMWS case in Saskatchewan (59). One 
negative control was used per 10 samples, per PCR event. The lowest detection limit of the 
nPCR assay was determined by 10-fold dilutions of Stoon7 spiked into pre-tested 100 mL 
aliquots of PCV2-negative semen. The concentration of Stoon7 was determined by an 
immunoperoxidase monolayer assay following one passage in PCV negative PK15 cells, as 
previously described (59).  
4.3.4 Sperm Morphological Analysis 
Spermiograms were prepared by mixing approximately 20 mL of eosin nigrosin sperm 
morphology stain (5.0 g nigrosin, 0.83 g eosin Y, 75 mL sterile distilled H2O with pH adjusted to 
6.8) with 20 mL of semen in extender, as previously described (19). One slide was prepared per 
boar per collection, and slides were stored at room temperature until examination of 200 cells per 
slide under 10003 oil emersion magnification to determine the ratio of live to dead sperm cells 
and specific morphological defects. Defects were categorized as: head (pyriform, tapered, 
microcephalic, macrocephalic, teratoid); midpiece (mitochondrial sheath defect, distal midpiece 
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reflex); principle piece (multiple tails, tail stump defect, coiled principle piece, accessory tails); 
detached normal heads; detached abnormal heads; proximal cytoplasmic droplet; knobbed 
acrosome; and the proportion of normal cells.  
4.3.5 Statistical Analysis 
The proportion of boars that had at least one positive PCV2-positive semen sample in 
each breed was compared with the Fisher’s Exact Chi-Square Test. Generalized Estimating 
Equations (52) (GEE) were used to evaluate the individual effect of age, time after stud entry, 
number of samples, and breed on the semen nPCR results in boars with at least one PCV2-
positive test. The effect of clustering was accounted for at the individual boar level.  
To determine the effect of seminal PCV2 status on semen quality, the mean percentage of 
live and normal sperm from nPCR positive and negative samples were compared using data from 
boars with both positive and negative samples. Since the data were normally distributed, the 
significance of observed differences was evaluated with the Student’s t-test. All statistical tests 
were conducted using statistical software (Stata Statistical Software 9.0; StataCorp LP, College 
Station, TX, USA). 
4.4 Results 
4.4.1 Animals 
All boars were positive for PCV2 Ab in serum by cELISA prior to initiating semen 
collections. No boars within the facility presented with PMWS or PCVD during the study. 
Because boars were sampled only during commercial production phases, the average time 
between individual collections for all boars was 11 ± 8.9 days (range 2 to 81). Of the 903 semen 
samples collected from 43 boars, serial collections were analyzed over 7.4 ± 1.1 months (range 
6.5 to 9).  
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4.4.2 nPCR Assay 
PCV2 DNA was detected by nPCR in 30 of 903 semen samples (3.3%) from 13 (30.2%) 
boars tested (Figure 4.1). PCV2 DNA was only detected in Duroc and Landrace boars. While the 
study was not balanced by breed, three of five Duroc boars (60%) and 10 of 23 (43.5%) 
Landrace boars had at least one PCV2-positive semen sample. The remaining 30 boars composed 
of Hamline (five), Large White maternal (six), Large White paternal (two), and Meishan-
synthetic (two) breeds, did not shed PCV2 in semen, as detected by nPCR (33.9 to 49.3 weeks of 
age at collection). The lowest detection limit of the modified nPCR was 9.7 × 10-4 TCID50/mL. 
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 Piga Totalb 32c 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 94
DU1 1/27      1 2 1/3 2 2 2 1 2 3 4 2 3 
DU2 1/10 1 1/2  1 1 1 1 3          
DU3 4/9  1/1  1/2 1/1 1  1/4          
LR1 1/22        2 1/4 3 3 3 2 2 2 1  
LR2 1/27  1 4 4 4 3 1/4 3 4         
LR3 2/36       1 1/4 3 1/4 5 4 5 4 4 2  
LR4 3/23 1  3 1/4 4 2 2/4 4 1         
LR5 1/16    1/2 3 1 1 3 4 1  1      
LR6 5/23  1/1 1/4 1  2 1/3 2/3 3 3 3       
LR7 8/27   1 3/3 2/4 2/4 1/3 3 3 3 3       
LR8 1/24  3 1/4 4 3 3 4 3          
LR9 1/16 1/1 2 2 1 2 3 2 3          
LR10 1/24 1 4 3 1/3 3 4 3 3          
Pos 30 1 3 2 7 3 2 5 5 1 1 0 0 0 0 0 0 0 
Total 284 4 14 21 25 25 25 28 41 24 16 16 9 9 9 10 5 3 
 
Figure 4.1: Results of nPCR to detect PCV2 DNA in semen from 13 boars with a positive 
sample from February 2002 to September 2003 (n=43 boars tested).  
From 13 boars with a positive semen sample:  
       254 semen samples were negative for PCV2 DNA;      
       30 semen samples were positive for PCV2 DNA (n=903 semen samples tested); 
       no semen collected. 
The number of positive samples of the total is shown as a fraction.  
a. Pig identification based on breed: DU=Duroc; LR=Landrace. 
b. Number of positive semen samples collected of total tested by nPCR for each boar. 
c. Age of boar in weeks; 4 week intervals. 
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4.4.3 Statistical Analysis 
No PCV2-positive semen samples were detected after 71 weeks of age, and there were a 
number of boars from each breed with no sample collected before 71 weeks of age. When those 
boars were omitted from the analyses, only two boars remained in each of those breed groups 
that had no boars with a PCV2-positive semen sample. There was no significant difference in the 
proportion of positive Duroc (2/3) or Landrace (10/20) boars with tests taken before 71 weeks of 
age (P=1). 
Because no positive PCV2 nPCR results were obtained after 71 weeks of age, samples 
collected after 71 weeks were excluded from the analysis of the effect of age on the PCV2 status 
of the sample. Only samples from boars with at least one positive PCV2 semen nPCR result were 
included. This made the interpretation of the effect of age more conservative. A model that 
included all of the negative samples after 71 weeks of age would increase the calculated odds of 
a sample being nPCR-negative with increasing age. Breed and the number of samples analyzed 
per boar were not significant predictors of the PCV2 semen status. Semen nPCR test results were 
less likely to be positive as age and the time after entry increased; however, these variables could 
not be evaluated together in a single model because they increase consistently together and their 
effects would be additive in the model (colinearity). With age as a continuous predictor, the 
effect on the PCV2 semen nPCR result was not linear. The final model evaluating the effect of 
age used age dichotomized as ≤52 weeks or >52 weeks and an exchangeable correlation structure 
(correlation between results from the same animal is the same at different time points). A semen 
nPCR test was 2.6 times more likely to be positive when collected from boars that were ≤52 
weeks of age (P=0.02; 95% CI of the OR 1.2 to 5.5). The final model evaluating the effect of the 
time from entry used the time from entry dichotomized as ≤26 weeks after entry or >26 weeks 
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after entry and an exchangeable correlation structure. A semen nPCR test was 3.0 times more 
likely to be positive when collected from boars that were ≤26 weeks from entry (P=0.01; CI of 
the OR 1.3 to 6.9). 
Sperm morphology analysis was performed on a subset of boars in this study: 10 PCV2-
shedding boars (199 smears; boar ID: DU2, DU3, LR2, LR4–LR10) and eight boars that did not 
shed PCV2 in semen (115 smears: data not shown) to determine the effect of PCV2 semen status 
on semen quality (based on the proportion of live and morphological normal cells). There was no 
significant difference between the proportion of live sperm (P=0.16) or morphologically normal 
sperm (P=0.54) between positive and negative samples. This did not change if a more complex 
analysis (GEE) was used to account for the effect of results of sperm analysis clustering on an 
individual animal basis (analysis not included).  
4.5 Discussion 
PCV2 DNA was detected in semen from 30.2% of naturally-infected boars and in 3.3% 
of semen samples collected from a commercial artificial insemination stud. PCV2-shedding in 
semen was sporadic in frequency and was detected over a period of up to 27.3 weeks. Of the 43 
boars tested in this study, 73.3% of the PCV2-positive semen tests came from five boars, and we 
observed marked variation in the duration and number of individual PCV2-positive semen 
samples in each boar. 
Boars ranged from 33.9 to 149.3 weeks of age for the period of this study; however, 
semen samples were more likely to be PCV2 DNA positive when collected from younger boars. 
The observation that no PCV2 positive semen samples were collected after 71 weeks of age and 
that younger boars were more likely to have PCV2-positive semen may be of importance to the 
swine industry. However, care must be taken in the interpretation of this result, as the number of 
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animals in this study was small and may not be representative of the population. Semen quality 
(proportion of live and morphologically normal cells) was not affected by the presence of PCV2 
DNA in semen when PCV2-shedding and non-shedding boars were compared. Because a small 
number of animals were evaluated and the within and between animal variability was high, 
differences attributed to the presence of PCV2 DNA in semen would be difficult to detect. 
All boars were positive for PCV2 Ab in serum before collection, but did not exhibit any 
PCVD; therefore, PCV2 seminal shedding may occur in the absence of clinical disease. It is not 
known if PCV2 detected by nPCR in semen was infectious or the quantity of virus present. 
Molecular assays are an efficient detective method to determine the presence of the virus; 
however, PCV2 virus isolation from semen has not been reported. Similarly, PRRSV RNA is 
detected in semen by PCR (44); however, transmission studies have proven that exposure of gilts 
to PRRSV-infected semen results in seroconversion and isolation of PRRSV from tissues in 
infected gilts (189). PCV2 shed in semen may contribute to the infection of susceptible sows and 
fetuses upon breeding; however, PCV2 isolation from semen or a bioassay using PCV2-
susceptible animals is required to confirm the potential infectivity of PCV2 in semen.  
Observations regarding PRRSV may be analogous to PCV2, as PRRSV causes a 
persistent infection in boars (43). Landrace, Yorkshire, and Hampshire boars infected 
experimentally with PRRSV demonstrate variability in the duration of PRRSV seminal shedding 
among breeds (42). 
The observed trend of differences in breed susceptibility to PRRSV shedding in semen 
requires further study of variable host factors in PRRSV persistence and resistance. PCV2 DNA 
was detected in semen from Duroc and Landrace boars only; however, the semen of the 
Hamline, Large White maternal, Large White paternal, and Meishan-synthetic boars were 
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negative for PCV2 DNA. Boars were not tested over a constant range in age or time after entry 
into the stud, and the total number of individual samples or breeds was not equal among boars. 
Whereas no interpretation regarding the susceptibility of shedding of PCV2 DNA with respect to 
breed can be made from this study, these observations warrant further study. 
Further investigation into the effects of breed and age on the shedding characteristics of 
PCV2 in semen is needed. The frequency of PCV2 DNA detected in semen in this study was low 
and sporadic, and regularly scheduled collections over time would further discern the temporal 
dynamics of viral shedding. It is not known if nPCR of raw semen versus extended semen would 
improve the detection of PCV2; however, it has been reported that PCV DNA is more often 
detected in the seminal fluid and nonsperm cell fractions of boar semen (108). It must be 
considered that boars seropositive for PCV2 may have persistent shedding in semen, and testing 
for PCV2 in semen may be required for commercial artificial insemination studs supplying 
semen to PCV2-susceptible sows. The significance of PCV2 DNA in semen as it relates to the 
transmission of the virus and its effects on reproductive success is currently unknown; however, 
it was determined in this study that PCV2 DNA in semen does not appear to adversely affect 
semen quality. In addition, the results presented in this study confirm the sporadic and long-term 
shedding of PCV2 DNA in semen from naturally-infected boars and suggest that boar age and 
possibly breed may contribute to the persistence of PCV2-shedding in semen. 
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CHAPTER 5 
 
DEVELOPMENT AND VALIDATION OF A SYBR GREEN REAL- 
TIME PCR FOR THE QUANTIFICATION OF PCV2 IN SERUM, BUFFY COAT, 
FECES, AND MULTIPLE TISSUES 
Vet Micro. 2009. McIntosh KA, Tumber A, Harding JCS, Krakowka S, Ellis JA, Hill JE. 
This research was conducted in 2005 to 2006. 
 
5.1 Abstract  
The emergence of multiple genotypes of PCV2, as demonstrated by phylogenetic analysis 
of whole genome or capsid sequences, makes it necessary to have quantitative diagnostic assays 
that perform equally well on all strains. The objectives of this study were to develop and validate 
a novel real-time PCR assay targeting the highly conserved Rep gene (ORF1) and investigate the 
effects of diagnostic specimen choice on its performance. The assay was tested in naturally-
infected conventional pigs, experimentally-infected gnotobiotic pigs, and plasmid-spiked 
negative serum, lung tissue, and feces and found to have a linear detection range of 2.2 × 103 to 
2.2 × 1010 copies of PCV2 per mL. The assay successfully detected and quantified PCV2 DNA 
in serum, buffy coat, feces, and multiple lymphoid (bronchial, mesenteric, and superficial 
inguinal lymph nodes, thymus, tonsil, ileal Peyer’s patches, and spleen) and non-lymphoid 
(myocardium, lung, kidney, liver, and gluteal muscle) tissues from naturally-infected pigs. 
Across all tissues and sera of naturally-infected pigs, the mean PCV2 concentration was 3.0 logs 
higher in wasting versus non-wasting pigs. PCV2 concentration measured by tissue culture and 
immunohistochemical staining in homogenized liver samples of experimentally infected 
gnotobiotic pigs were compared to the concentrations estimated by quantitative PCR. Similar 
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trends were noted with increasing PCV2 concentration detected in subclinically-infected to 
severely PMWS-affected pigs across all assays. Our diagnostic assay was developed with a 
conserved target sequence, and performed efficiently in the quantification of PCV2 in a variety 
of tissues from pigs infected naturally and experimentally. 
5.2 Introduction 
Non-pathogenic PCV was discovered in 1974, as a picornavirus-like contaminant of a porcine 
kidney tissue culture cell line (PK15) (215). PCV consists of a single stranded circular DNA 
genome of 1.7 kb, is non-enveloped, and is approximately 17 nm in diameter. In the mid-1990s, 
PMWS was recognized and found to affect primarily pigs 6 to 15 weeks of age (47;89). 
A genetically (152) and antigenically (11) distinct PCV was recovered from a PMWS-
affected pig in 1996 (59). The pathogenic PCV was subsequently named porcine circovirus type 
2. PMWS is characterized by wasting or unthrifty pigs, jaundice and respiratory distress, 
accompanied by gross and/or histopathological lesions affecting multiple organs and tissues 
(11;59;88). Pathologically, PCV2 is associated with interstitial pneumonia, hepatitis, 
lymphadenopathy, pancreatitis, myocarditis, nephritis, and enteritis (11;47). PCV2 is the 
etiological agent of PMWS and is found associated with additional disease syndromes including: 
congenital tremors (CT) (211), porcine respiratory disease complex (PRDC) (105), porcine 
dermatitis and nephropathy syndrome (PDNS) (8), abortion (228), and reproductive disorders 
(166). Diseases associated with PCV2 are now collectively termed porcine circovirus diseases 
(PCVD), or porcine circovirus associated disease (PCVAD). PCV2 nucleic acid or antigen 
associated with lesions in the tissues of affected pigs is the primary target for the diagnosis of 
PCVD in pigs.  
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An increasing number of herds globally are infected with PCV2; however, the infection 
remains subclinical in the majority of pigs. Progression to overt disease, or PCVD, requires 
coinfection with another pathogen (53) such as porcine respiratory and reproductive syndrome 
virus (PRRSV) (10), porcine parvovirus (PPV) (61;115), Mycoplasma hyopneumoniae (180), an 
immune stimulus (113;114), or cofactor which may include early weaning or inappropriate 
management practices (194).  
Recently, viral load has been associated with PCVD clinical severity in pigs (112) and it 
has become more desirable to use quantitative methods to determine the magnitude of PCV2 
infection. In addition, real-time PCR is generally more rapid, less labour intensive, less 
expensive, and may be more reliable than conventional PCR. Several previously published 
assays exist using either a probe type (29;45;169;231), or a SYBR green (230) real-time PCR 
methodology. PCV2 differential diagnostic assays are now available due to the increasing 
concern regarding the spread of potentially more virulent genotypes of PCV2 (57); however, 
there is conflicting evidence (13;71).  
The objectives of this study were to develop and validate a novel SYBR green real-time 
PCR assay targeting ORF1 (Rep) exploiting oligonucleotide primer binding sites conserved 
across 244 characterized PCV2 genomes, and to investigate the effects of diagnostic specimen 
choice on its performance. The assay was designed to target all genotypes of PCV2 (PCV2a/2b) 
(71), or genogroups (PCV2-G1/G2) (13), and was tested to determine its versatility and 
performance in multiple tissues using naturally-infected conventional pigs, experimentally-
infected gnotobiotic pigs, and plasmid-spiked PCV2-negative serum, lung tissue, and feces. 
Historically, homogenized and serially diluted pig tissues or serum have been applied to PK15 
cells to determine the tissue culture infective dose (TCID50) or concentration of PCV2. This 
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method of quantification is labor intensive, expensive, and extremely time consuming as it 
requires the maintenance of tissue culture, followed by fixing and immunostaining techniques. In 
this study, serum and homogenized liver samples from experimentally-infected gnotobiotic pigs 
were tested to determine the PCV2 TCID50 and were compared with the SYBR green real-time 
PCR assay described here. 
5.3 Materials and Methods 
5.3.1 Oligonucleotide Primer Design 
 Complete genome sequences of PCV2 (199 sequences) and PCV1 (23 sequences) were 
retrieved from Genbank. Additional unpublished PCV2 genome sequences derived from 
Canadian PCV2 strains (45 sequences) were received from Dr. Carl Gagnon (Faculty of 
Veterinary Medicine, University of Montreal, St. Hyacinthe, QC, Canada). Signature Oligo 
software (LifeIntel, Port Moody, BC, Canada) was used to identify PCV2-specific sequences. 
Output from Signature Oligo was used to guide oligonucleotide primer selection with Primer3 
(196). Specificity of primer sequences was confirmed by comparison to a local database of PCV 
sequences and to the GenBank DNA database using BLASTn (16) configured for short, nearly 
exact matches (word size seven, expect value 1000).  
5.3.2 Conventional PCR 
The conventional PCR reaction mixture for each of the assays PCV2-492 bp and PCV2-
83 bp was 1× PCR buffer (75 mM Tris–HCl (pH 8.8), 20 mM (NH4)2SO4, 0.01% (v/v) Tween 
20), 2 mM MgCl2, 0.8 mM each primer, 0.25 mM each dNTP, 1.25 U Taq DNA polymerase 
(Fermentas Taq DNA polymerase; Fermentas, Mississauga, ON, Canada), 2 µL template, and 
was made up to 50 µL with sterile water. Amplification of DNA for PCV2-492 bp was achieved 
by 3 minutes at 94ºC, followed by 40 cycles of 30 seconds at 94ºC, 1 minute at 60 ºC, and 1 
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minute at 72ºC, and a final extension of 5 minutes at 72ºC. Amplification for PCV2-83 bp was 
performed similarly, but with an annealing temperature of 59ºC. PCR reactions were performed 
in a DNA Engine (PTC-200) thermal cycler (MJ Research Inc., Watertown, MA, USA), and 
amplicons were visualized by ethidium bromide staining on a 1.5% agarose gel with a DNA 
ladder (GeneRuler DNA Ladder Mix; Fermentas, Burlington, ON, Canada).  
5.3.3 Standard Curve 
A region of the PCV2 genome corresponding to nucleotides 179-670 of GenBank 
Accession DQ220739 was PCR amplified from extracted (DNeasy Tissue Kit; Qiagen Inc., 
Mississauga, ON, Canada) porcine lymph node using primers PCV2 492F (5’-
TATTGTTGGCGAGGAGGGTA-3’) and PCV2 492R (5’-TGGTAACCATCCCACCACTT-3’). 
The resulting amplicon of 492 bp (GenBank Accession EU126886) was ligated into a cloning 
vector (pCR 2.1-TOPO; Invitrogen, Burlington, ON, Canada) and used to transform competent 
E. coli. Plasmid DNA was recovered from an overnight culture (Wizard Plus SV Minipreps 
DNA purification System; Fisher Scientific Ltd., Nepean, ON, Canada) and quantified by a 
dsDNA assay kit (Quant-iT PicoGreen; Invitrogen, Burlington, ON, Canada). Fluorescence 
intensity was measured by a microplate reader (NOVOstar; BMG Lab technologies Ltd.; 
Durham, NC, USA). The plasmid concentration was converted from mass to copy number based 
on a plasmid size of 4423 bp (492 bp insert, 3931 bp vector) and assuming 650 g mol-1 for each 
bp of DNA, and was calculated to be 2.2 × 109 per µL. Conventional PCR reactions for 
development of the plasmid with PCV2-492 bp insert (pl-492) were conducted using reaction 
components and conditions described above. A 10-fold dilution series of pl-492 was used to 
generate the real-time PCR standard curve. 
 
 55
5.3.4 PCV2 Naturally-Infected Pigs and Clinical Specimen Collection 
All procedures were conducted in accordance with the University of Saskatchewan’s 
Committee for Animal Care and Supply (permit #20060004). In October 2006, naturally PCV2 
infected wasting (n=3) and age-matched non-wasting (n=3) pigs originating from a biosecure 
conventional commercial farrow-to-finish facility, containing 1200 sows, were selected for this 
study (Table 5.1). The selected pigs were tagged, bled via the jugular vein, then transported to 
the Western College of Veterinary Medicine, Saskatoon, Saskatchewan, and euthanized by 
cranial captive bolt. The postweaning mortality on the farm was approximately 15.9% for the 
period immediately preceding this study and PCVD had been diagnosed based on unthriftiness, 
dyspnea, diarrhea and jaundice, and was confirmed by PCV2 immunohistochemical staining and 
the presence of typical histological lesions in the tissues of selected pigs (Prairie Diagnostic 
Services, Saskatoon, SK, Canada). Serum, buffy coat, lymphoid (bronchial, mesenteric, and 
superficial inguinal lymph nodes, thymus, tonsil, ileal Peyer’s patches, and spleen) and non-
lymphoid (myocardium, lung, kidney, liver, and gluteal muscle) tissues and feces were collected 
from each pig. 
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Wasting pigs Non-wa ng pigs sti
 
Approximate 
age (in weeks)
ID Gross lesions ID Gross lesions 
 
9 21 Poor body condition; enlarged abdomen; few 
small areas of congestion on pole of spleen; 
pale kidneys; depleted thymus; non-collapsed 
lungs with prominent lobular pattern; 
anteroventral consolidation (20%); dilated 
and fluid-filled spiral colon 
36 Slightly enlarged 
systemic LN 
9 26 Poor body condition; very enlarged systemic 
LN; non-collapsed caudal lung lobes; 
cranioventral bronchopneumonia 
30 No abnor al findings m
13 3 Poor body condition; enlarged inguinal LN; 
multiple diffuse white pinpoint foci on 
kidneys; depleted thymus & Peyer’s Patch; 
non-collapsed lungs; excess straw colored 
fluid in abdomen; full stom
44 Enlarged LN 
systemically; few small 
foci bilaterally 
ach 
 
Table 5.1: Gross pathological lesions of age-matched conventional pigs tested by a SYBR green 
real-time PCR for PCV2 in serum, buffy coat, feces, and multiple tissues. 
ID=pig identification number; LN=lymph node. 
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5.3.5 PCV2 Experimentally-Infect Pigs and Clinical Specimen Collection 
In addition to samples from PCV2 naturally-infected conventional pigs, terminal s um 
and liver samples were collected and  PCV2 experimentally-infected and non-
infected gnotobiotic pigs in accordan tutional Laboratory Animal Care and Use 
Committee of The Ohio State Univer 2000A0174, 2002A0046, and 2005A0 95. 
Briefly, gnotobiotic piglets were infected with 1.0 mL PCV2 OSUp3 (5.0 × 108 TCID50/mL)
intranasally at 3 days of age and terminated when moribund or at 35 days of age, as previously 
described (60;111;115). PCV2 viral titers from homogenized liver samples were determined for 
PCV2-infected and non-infected gnotobiotes (114). Previously published criteria were used to 
determine the clinical status of the infected gnotobiotic pigs (112). 
5.3.6 Template DNA Preparation 
Clotted and EDTA-treated blood samples were centrifuged at 500 × g for 15 minutes, and 
serum and buffy coat were removed, r  stored in sterile 1.5 mL tubes. All po ne 
samples were stored at -70ºC until D  DNA was isolated from samples including 
terminal serum, buffy coat, lymphoi esenteric, and superficial inguinal lymph 
nodes, thymus, tonsil, ileal Peyer’s p een) and non-lymphoid (myocardium, lung, 
kidney, liver or liver homogenate, scle) tissues using a commercial DNA 
extraction kit (DNeasy Tissue Kit; Qiagen Inc., Mississauga, ON, Canada), according to the 
manufacturer’s instructions. Sample volumes for serum and buffy coat were 80 and 50 µL, 
respectively, and were eluted in 100 µL of buffer. The final elution volume for tissue sam les 
(sample size 15 to 26 mg or 80 µL of liver homogenate) was 200 µL. DNA was extracted from 
fecal samples (190 to 221 mg) using a commercial kit (Qiamp DNA Stool Mini Kit; Qiagen Inc., 
ed Gnotobiotic 
 processed from
ce with The Insti
sity protocols #
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espectively, and
NA extraction.
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Mississauga, ON, Canada), according nufacturer’s instructions, and eluted in 200 µL of 
buffer. All extracted samples were sto  real-time PCR testing. 
5.3.7  Real-time PCR 
Each quantitative real-time PCR reaction was performed using 12.5 µL of SYBR green 
reaction mix (Brilliant SYBR Green QPCR Master Mix; Stratagene, La Jolla, CA, USA), 150 
nM of each primer PCV2-83F and PC reference dye (ROX; Stratagene, La Jolla, 
CA, USA), 3 µL of template, and ma 25 µL with sterile water. All real-time reactions 
(standards, unknown samples, and controls) were performed in duplicate in neighboring wells on 
the sample plate. Results reported are an average of the duplicates. Real-time PCR reactions 
were performed in a thermal cycler and fluorescence detection system (Mx3005P; Stratagene, La 
Jolla, CA, USA). Cycling conditions were 10 minutes at 95ºC, followed by 45 cycles of 30 
seconds at 95ºC, 1 minute at 59ºC, and 30 seconds at 72ºC. A dissociation curve was performed 
after amplification by a gradual rise in temperature from 55 to 95ºC, and the fluorescence signal 
was measured every 0.5ºC. Fluorescence normalization and data analysis was performe by 
thermal cycler program software (MxPro-Mx3005P v.3.00; Stratagene, La Jolla, CA, USA).
5.3.8 Sensitivity and Assay Cutoff Determination  
Serum, lung tissue, and feces from a PCV2-negative pig, as determined by conventional 
PCR with primers PCV2 492F and PCV2 492R, were spiked with known concentrations of pl-
492 in a serial 10-fold dilution series. DNA extraction and real-time PCR were performe on 
each sample, as described above. 
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5.4 Results 
5.4.1 PCV2-specific Oligonucleotides 
Potential primer sequences were identified by determination of sequence regions 
predicted annealing temperature and show little 
otential for dimerization and self-interaction. Based on these criteria, oligonucleotides PCV2-
3F (5’-AAAAGCAAATGGGCTGCTAA-3’) and PCV2-83R (5’-TGGTAACCATCCCACCA 
TT-3’) were selected for real-time PCR protocol development. These primers amplify an 83 bp 
gion of the Rep gene (ORF1) of PCV2 corresponding to nucleotides 588 to 670 on DQ220739.  
.4.2 PCR Optimization and Specificity 
A series of PCR amplifications across an annealing temperature gradient indicated that 
e optimal annealing temperature for PCV2-83F and PCV2-83R was 59ºC. Primers were tested 
d 
amplifi
a (6.6 
8 -1
7 0
3
as applied to tested samples. 
e ted as not quantifiable (i.e. below the detection limit of the 
conserved across all available PCV2 genome sequences and not found in PCV1 genomes. 
Primers were required to be closely matched in 
p
8
C
re
5
th
in conventional PCR reactions against one PCV1 and one each of PCV2a and 2b templates an
cation of the 83 bp product was observed only with PCV2 templates (data not shown). 
Products of three independent amplifications with PCV2-83F and PCV2-83R were sequenced to 
confirm the specificity of the target (data not shown).  
5.4.3 Real-time PCR Performance 
A plasmid standard curve was conducted over a range of target DNA concentr tions 
× 10  to 6.6 × 10  copies of plasmid pl-492 per 25 µL reaction; Figure 5.1). The linear portion of 
the standard curve was found to span 6.6 × 10  to 6.6 × 10 ; therefore, a lower detection limit (or 
cutoff) of 6.6 copies per 25 µL reaction, equivalent to 2.2 × 10  copies per µL was established. 
This cutoff corresponded to a threshold cycle (Ct) of 35.47 and w
Sampl s with a Ct > 35.47 were repor
 60
test) fo
d 
 
r PCV2 DNA. Extracted samples with a copy number exceeding 6.6 × 107 per 25 µL 
reaction, or a Ct < 10.81 were diluted 1:10 using sterile water and re-tested. The dilution factor 
was taken into consideration when calculating copies of PCV2 in the original sample. A 
dissociation curve (Figure 5.2) using pl-492 (6.6 × 108 to 6.6 ×10-1 copies per 25 µL reaction) 
and serum, buffy coat, multiple tissues, and feces from PCV2-infected wasting pig #3 (Table 5.2) 
was made. Dissociation, or the melting temperature (Tm) of the 83 bp PCR product occurred 
between 77.1 and 77.8ºC. Extraction and PCR negative controls consisting of sterile water an
reaction mix did not produce any amplification product; therefore, no peaks were observed 
(Figure 5.2).  
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Figure 5.1: Standard curve plot (copy number vs. threshold cycle (Ct) with regression and 
efficiency) for PCV2 DNA in plasmid (pl-492) detected by SYBR green real-time PCR. 
Individual data points corresponding to duplicate wells containing 25 µL reactions are plotted. 
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Figure 5.2: Typical dissociation curve of PCV2 PCR product following 45 cycles of 
amplification of plasmid positive control pl-492 and porcine samples. Samples tested include 
serum, buffy coat, feces, lymphoid (bronchial, mesenteric, and superficial inguinal lymph nodes, 
thymus, tonsil, ileal Peyer’s patches, and spleen) and non-lymphoid (myocardium, lung, kidney, 
liver, and gluteal muscle) tissues. Dissociation of PCR product occurred at 77.8ºC and no 
amplification w
 
as seen in negative controls and negative samples, as indicated. 
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 Wastinga Non-wastinga 
Tissue Pig 3 Pig 21 Pig 26 Pig 30 Pig 36 Pig 44 
Serum 1.23×109 2.91×1010 3.30×108 0 1.51×105 9.79×106 
3.69×106 8.11×107 8.13×107 8.22×103 0 2.55×106 Buffy coat 
Feces 2.26×109 7.04×1010 1.57×109 1.84×107 5.99×107 1.74×108 
BLN 0 1.11×109 1.82×108 0 0 2.05×106 
MLN 1.17×1010 1.15×1011 1.83×109 0 0 1.43×105 
ILN 3.03×107 7.99×108 9.24×108 0 0 9.91×105 
Tonsil 6.07×106 8.04×1010 3.89×108 2.38×104 0 0 
Thymus 0 4.35×1010 5.81×108 5.32×105 0 0 
PP 3.21×107 1.02×104 8.26×108 4.82×105 0 3.22×103 
Spleen 4.33×107 2.98×109 2.18×108 0 0 0 
Heart 4.03×107 2.23×107 2.22×108 1.43×104 0 6.26×105 
Lung 1.11×109 1.79×108 4.75×106 2.51×104 0 8.37×104 
Kidney 7.65×108 5.32×108 4.04×107 0 0 6.33×104 
Liver 1.86×109 5.52×108 4.80×107 0 0 6.33×104 
GLM 1.13×108 4.67×107 4.75×108 0 6.96×105 8.76×105 
 
Table 5.2: Copy number of PCV2 genomes detected in serum, buffy coat, feces, and multiple 
tissues for 3 wasting (3, 21, 26) and 3 non-wasting (30, 36, 44) age-matched pigs. Values 
reported were calculated from the average of samples tested in duplicate. 
BLN=bronchial lymph node; MLN=mesenteric lymph node; ILN=ileal lymph node; PP=Peyer’s 
patch; GLM=gluteal muscle. 
a Copies per mL or g 
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5.4.4 Effects of Template Source on Sensitivity 
The copies of PCV2 genomes detected in serum, lung, and feces were affected variably 
by inhibitors and the DNA extraction process (Figure 5.3). Of the three tissue types, the number 
of copies detected in serum was the most accurate until approaching the lower detection limit 
where a 2 log difference in expected versus detected copies was observed. In both lung and 
feces, the target copy number measured was less than the expected copy number by 
approximately 2 logs. A 1:10 dilution of extracted lung tissue improved detection to within a log 
(Figure 5.4), and subsequent dilution to 1:100, 1:500 and 1:1000 gave no further improvement. 
Dilution did not improve detection in feces (data not shown). A lower detection limit or cutoff 
value was assigned based on the plasmid standard curve, as described above. 
5.4.5 Quantification of PCV2 in Naturally- and Experimentally-Infected Gnotobiotic Pigs 
All samples were measured (mL) or weighed (mg) prior to extraction. All samples were 
expressed as the number of copies of PCV2 genomes per gram or mL of original sample from 
biotic 
e 
oncentrations of PCV2 DNA were consistently higher in the wasting versus non-wasting pigs 
able 5.2). In experimentally infected gnotobiotes, a similar trend of increasing viral load with 
creasing severity of the observed clinical outcome was observed for both serum and 
omogenized liver (Figure 5.5). In addition, homogenized liver samples tested by tissue culture 
nd immunohistochemical staining (expressed as TCID50) and real-time PCR tested samples 
igure 5.5) illustrate similar trends in increasing viral load from subclinical to severely PMWS-
affected status. 
 
either naturally-infected conventional pigs (Table 5.2), or experimentally-infected gnoto
igs (Figure 5.5). Although the data set is small and representing only three pigs per group, thp
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igure 5.3: Copies of plasmid DNA spiked into (a) serum, (b) lung, and (c) feces followed by 
NA extraction and real-time PCR to determine the effect of extraction and tissue type on the 
uantification of PCV2. The lower detection limit (broken line) is based on the standard curve 
igure 5.1), and is indicated (broken line). 
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Figure 5.4: Determination of the effects of template dilution on quantification of plasmid DNA 
in lung tissue. 
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Figure 5.5: Quantification of PCV2 in serum and liver homogenate derived from experimentally 
infected gnotobiotic pigs. Titers (based on tissue culture infective dose 50 (TCID50)) from 
homogenized liver samples with clinical characteristics (status/outcome based on previously 
 
 
 
 
 
 
published criteria by Krakowka et al., 2005) are indicated. 
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5.5 Discussion 
 
The SYBR green real-time PCR described here was developed to target the replication-
associated gene (ORF1) of PCV2. The majority of published real-time PCR assay primers, 
including both probe and SYBR green-based assays, target the capsid gene (ORF2) 
(29;45;73;169;230). The efficiency of a probe or a primer in a quantitative PCR assay will be 
variably affected by mismatches between the oligonucleotide and the desired target sequence. 
Depending on the degree of mismatch, this inefficiency will reduce the accuracy of 
quantification or, in more extreme cases, result in false-negatives. Thus it is desirable to choose 
target sequences that are strongly conserved within the target population. Upon analysis of whole 
PCV2 genome sequences, it is recognized that ORF1 is more conserved across all PCV2 
sequences than ORF2 (50). In addition, ORF1-based primer targets are conserved across 
genotypes 2a and 2b of PCV2 when compared with the ORF2, encoding the capsid protein. 
Since ORF2 is not as well conserved, a more reliable and quantifiable real-time assay would 
target the ORF1 region of the PCV2 genome which is a considerable advantage of the assay 
described here over previously reported diagnostic tests.  
Serum, lung tissue, and feces from a PCV2 negative pig were spiked with known 
quantities of a plasmid containing a PCV2 DNA target. These samples were used to determine 
what effect, if any, resulted from inherent PCR inhibitors, or the DNA extraction process on the 
assay sensitivity and the quantification of PCV2. In lung tissue and feces, the detected copies of 
PCV2 genomes were consistently 1 to 2 logs lower than the expected value; however, in serum, 
uantification in feces (data not shown). This suggests that in lung samples and in samples 
expected and observed quantities were in good agreement. A 10-fold dilution of the extraction 
material improved quantification in lung tissue (Figure 5.4), but did not improve the 
q
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exceeding the detectable range of the assay (>6.6 × 107 copies per 25 µL reaction), a dilution 
ries of the extraction volume in random samples is recommended to determine the ideal 
ilution for the data set; therefore, one can achieve the most accurate quantification of PCV2 in 
e original sample.  
A very low concentration of PCV2 DNA was detected in samples of spiked lung tissue 
that were below the calculated lower detection limit of the assay (i.e. not quantifiable and below 
the broken line; Figure 5.3b). The pig used as the source of this tissue was determined to be 
PCV2 negative using a conventional PCR assay. However, it is possible that PCV2 was present 
at a level below the detection limit of conventional PCR; therefore, a positive result could occur 
from the additive effect of spiking the samples with the plasmid PCV2 target DNA. In future 
studies, PCV2-negative gnotobiotic pig tissues should be used to further clarify this issue.  
Serum, buffy coat, feces, and various tissues were tested from non-wasting and PCVD-
affected or wasting conventional pigs infected with PCV2 (Table 5.2). PCV2 was detected in all 
tissue types in wasting pigs with the exception of the bronchial lymph node (LN) and the thymus 
from pig #3. In contrast, several tissues in one or more of the non-wasting pigs (serum, buffy 
coat, bronchial LN, mesenteric LN, ileal LN, tonsil, thymus, Peyer’s patch, spleen, heart, kidney, 
 
ssay was able to quantify a range of PCV2-positive samples from 3.22 × 103 to 1.15 × 1011 per 
L or g of sample, and a trend was observed where virus load was higher in the majority of 
ssues of PCVD-affected pigs. This is consistent with observations made elsewhere 
9;112;200). However, the variability of PCV2 concentration should be investigated in larger 
ata sets to determine if it is real, and of any biological importance. 
se
d
th
liver, and gluteal muscle) did not have detectable or quantifiable levels of PCV2 DNA. The
a
m
ti
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The quantity of PCV2 detected by real-time PCR in serum and homogenized liver 
mples from experimentally-infected gnotobiotic pigs increased with the severity of clinical 
isease. This trend was analogous to the calculated tissue culture infective dose when compared 
ith the severity of disease. This suggests that a relationship may exist between the quantity of 
PCV2 DNA in serum and liver, and the severity of PCVD, as previously reported (112;200).  
In conclusion, the SYBR green real-time PCR assay described here was tested in 
naturally-infected conventional pigs, experimentally-infected gnotobiotic pigs, and plasmid-
spiked negative serum, lung tissue, and feces and found to have a linear detection range of 2.2 × 
103 to 2.2 × 1010 copies of PCV2 per mL. The assay successfully detected and quantified PCV2 
DNA in serum, buffy coat, feces, and multiple lymphoid (bronchial, mesenteric, and superficial 
inguinal lymph nodes, thymus, tonsil, ileal Peyer’s patches, and spleen) and non-lymphoid 
(myocardium, lung, kidney, liver, and gluteal muscle) tissues. With the emergence of genotypes 
of PCV2, it is necessary to use a quantitative assay that is equally efficient across multiple 
isolates to maintain accurate quantification of PCV2, and therefore, possibly resolve the current 
issues related to viral load in tissues and associated disease state. The assay described in this 
ally those for virus targets, a 
eriodic re-evaluation of the assay in the context of recently emerged strains and genotypes is 
ssential to maintain the validity of the test. 
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study was developed with a conserved target sequence across 244 PCV2 sequences, and was 
successfully tested in multiple tissues, naturally-infected conventional pigs, and experimentally-
fected gnotobiotic pigs. As with any PCR-based diagnostic, especiin
p
e
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CHAPTER 6 
 
QUANTITATIVE PCR FOR PCV2 IN SWINE FECES IN A PCVD-AFFECTED 
COMMERCIAL HERD AND A NON-AFFECTED COMMERCIAL HERD 
Can Vet J. 2008. McIntosh KA, Harding JCS, Parker SE, Krakowka S, Allan G, Ellis JA. 
This research was conduction in 2006. 
 
6.1 Abstract 
This study examined if pigs in a PCVD-affected herd (n=100) had shed more PCV2 in 
their feces than pigs in a PCVD-nonaffected herd (n=101), and if differences in shedding among 
production stages within and between the herds existed. The PCV2-shedding was quantified by 
real-time PCR. The highest median PCV2-shedding was found in the nursery of the PCVD-
affected herd and in the grower of the PCVD-nonaffected herd. The PCV2-shedding was 
significantly higher in earlier stages (newly weaned, nursery, and pregrower) in the PCVD-
affected herd (Wilcoxon Rank Sum; P<0.001) compared with the PCVD-nonaffected herd. 
PCV2 DNA was not detected in a significant proportion of lactating sows (parity ≥3) in the 
PCVD-nonaffected herd (Fisher’s Exact Test; P=0.001). The results of this study suggest there 
may be an association between the presence of PCV2 in the feces of lactating sows and increased 
PCV2-shedding in younger pigs. 
6.2 Introduction 
First described in the mid-1990’s (88), PMWS was found to clinically affect pigs 7 to 15 
weeks of age with wasting, enlarged lymph nodes, dyspnea, diarrhea, pallor, and jaundice. In 
1998, PCV2 was isolated from a pig in Saskatchewan showing clinical signs of PMWS (59). In 
the last decade, other clinical syndromes have been recognized in association with PCV2 
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infectio
D; 
howeve
 shed more PCV2 in their feces than did pigs in a 
PCVD-nonaffected herd; and 2) to determine if there are differences in the amount of PCV2 shed 
in feces among production stages within and between a PCVD-affected and a PCVD-nonaffected 
commercial swine herd. 
n; these include the porcine dermatitis and nephropathy syndrome (PDNS) (151;195), 
congenital tremors (CT) (211), abortion (166), and reproductive disorders (109;228). For 
simplicity, diseases associated with PCV2 infection are now collectively termed porcine 
circovirus diseases (PCVD) (5;199), or porcine circovirus associated disease (PCVAD) (17).  
The general consensus among scientists is that PCV2 is the etiological agent of PCV
r, other infectious agents (53), stressors, or cofactors are required concurrently to 
exacerbate PCVD in pigs infected with PCV2. Coinfection with porcine reproductive and 
respiratory syndrome virus (PRRSV) (10;93), Mycoplasma hyopneumoniae (180), or porcine 
parvovirus (PPV) (61;115); immune stimulation (113;114); or production and weaning practices 
(194) can contribute to, or exacerbate, PCVD in PCV2-infected pigs. The PCV2 nucleic acid, or 
antigen, or both can be found in, and PMWS is characterized by, gross or microscopic lesions in 
multiple organs and tissues of infected pigs (11;59;88). PCV2 is shed in various secretions from 
both naturally- and experimentally-infected pigs, and in healthy versus PCVD-affected pigs via 
nasal, tonsillar, tracheobronchial, oropharyngeal, fecal, and urinary routes (200;207). 
Additionally, PCV2 DNA is detected in semen from experimentally- (119) and naturally- (146) 
infected boars. An association exists between the severity of clinical disease, or PCVD, in 
affected pigs and the PCV2 viral load that is found in tissues from affected animals (29;112); 
however, PCV2 quantified from fecal samples has not been reported in PCVD-affected versus -
nonaffected pigs, or across production stages. The objectives of this study were as follows: 1) to 
determine if pigs in a PCVD-affected herd
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6.3 Materials and Methods 
6.3.1 
dy. Both 
cted endemically with PCV2; however, the nonaffected herd (300 sows) had no 
linical evidence or diagnosis of PCVD and a long-standing postweaning mortality of <2%, 
hile the PCVD-affected herd (1200 sows) was experiencing a PCVD-related mortality of 
4.5% during the period of sampling.  
Based on prior testing of lymphoid tissue, the PCV2 genotypes present in each barn were 
etermined, as per a previously described method (87). In limited testing of lymphoid tissue, 
oncurrent PCV2a and PCV2b were detected in the PCVD-nonaffected herd, whereas PCV2b 
lone was detected in the PCVD-affected herd. PMWS was recognized as the primary clinical 
anifestation of PCVD in the affected herd; the diagnosis was based on observed jaundice, 
nthriftiness, and dyspnea, and confirmed by PCV2 immunohistochemical staining and the 
resence of typical histological lesions in the tissues of selected pigs (Prairie Diagnostic 
ervices, Saskatoon, SK, Canada). Based on clinical records and serologic testing, there was no 
vidence of PRRSV, Mycoplasma hyopneumoniae, swine influenza virus H1N1, Actinobacillus 
leuropneumoniae, or Haemophilus parasuis in either herd; however, the PCVD-affected herd 
ad experienced sporadic disease associated with A. suis and Streptococcus suis.  
Each barn was sampled in a cross-sectional manner with approximately 50 fecal samples 
eing collected from each of the feeding and breeding herds. From the feeding herd, 
Animals and sample collection  
Approximately 100 pooled fecal samples were collected from each of two commercial 
swine facilities in Saskatchewan practicing high-biosecurity procedures. Both facilities were 
farrow-to-finish operations housing Landrace and Large White sows, or their respective crosses. 
PCV2 vaccines were not used in either facility prior to collecting samples for this stu
barns were infe
c
w
1
d
c
a
m
u
p
S
e
p
h
b
 75
approximately 10 samples (range=10 to ected from each of five evenly spaced 
production weeks between weaning and market age (newly weaned (NW), nursery (NU), 
pregrower (PG), grower (GR), and finisher (FIN)) (Table 6.1). From the breeding herd, sampling 
was stratified by age with approximately 10 samples (range=7 to 14) collected from each of 
virgin (VG) and bred (BG) gilts, young (S ≤2) and old (S ≥3) sows (based on a parity of ≤2 or 
≥3), and breeding boars (B) (Table 6.1). 
 11) were coll
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Number of pens 
Production stage Age of pigs  
 PCVD-nonaffected PCVD-affected
Newly weaned (NW) 3-4 weeks 10 11 
Nursery (NU) 7-8 weeks 10 10 
Pregrower (PG) 11-12 weeks 10 10 
Grower (GR) 15-16 weeks 10 10 
Finisher (FIN) 22-24 weeks 10 11 
Virgin gilt (VG) 6 months 10 10 
Bred gilt (BG) 8-10 months 10 10 
Lactating sow parity ≤2 (S ≤2) 11-15 months 10 10 
Lactating sow parity ≥3 (S ≥3) 15+ months 14 11 
Boar (B) 12-24 months 7 7 
Total number of pooled fecal samples by barn n=101 n=100 
 
Table 6.1: The representative ages and the number of pens tested for each production stage in 
two commercial swine facilities (PCVD-nonaffected herd; PCVD-affected herd) tested for PCV2 
in pooled fecal samples by quantitative real-time PCR. 
S ≤2=young sow; S ≥3=old sow. 
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The barns were sampled on different days: PCVD-nonaffected herd (n=101 samples; 18 
0 =100 samples; 17 May 2006). However, all samples 
within 
ogenized, and 1 g of feces from each bag was stored in 
individ
 
Sept 2 06) and PCVD-affected herd (n
a barn were collected on the same day. The bred gilts, sows, and boars were housed in 
crates or stalls; therefore, the fecal samples collected from these animals represented the 
individual animal. By contrast, all other animals were housed in pens containing a variable 
number of pigs (Table 6.2). Fecal samples obtained from pens comprised multiple individual 
fecal samples and were considered pools. By using sterile gloves for each collection, samples 
representing separate defecation events from multiple pigs in a single pen were pooled into a 
sterile bag and transported in an insulated box to the laboratory for processing on the same day. 
Upon arrival, pooled samples were hom
ual sterile 15 mL conical tubes and frozen at -70°C until DNA extraction. 
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Barn NW NU PG GR FIN VG BG S≤2 S≥3 B 
PCVD-nonaffected 12 12 5-6 5-6 12 20 1 1 1 1 
PCVD-affected 20-25 20-25 20-25 20-25 20-25 4-5 1 1 1 1 
 
Table 6.2: The number of pigs housed per pen for each production stage in a PCVD-nonaffected 
herd and a PCVD-affected herd. Pooled fecal samples from each production stage in each barn 
were tested for PCV2 by quantitative real-time PCR. 
NW=newly weaned; NU=nursery; PG=pregrower; GR=grower; FIN=finisher; VG=virgin gilt; 
BG=bred gilt; S ≤2=lactating sow parity ≤2; S ≥3=lactating sow parity S ≥3; B=boar. 
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6.3.2 DNA Extraction and Quantitative PCR 
Fecal samples were extracted for DNA by using a commercial kit (QIAamp DNA stool 
ini kit; Qiagen, Mississauga, ON, Canada), following the manufacturer’s instructions for DNA 
olation from larger amounts of stool. Samples consisting of 1 g of homogenized feces were 
removed from -70°C and 10 mL of stool lysis buffer (ASL ini kit; 
Qiagen, Mississauga, On, Canada) was added immediate D
 pipetting 1 ad of 2 mL, of lysate from 10 mL of homogenized 
 lysis buffer. Extrac as stored at -70°C until quantitative real-time PCR 
iously described (1 ive SYBR green (DNA binding dye) real-time 
 plasmid standard k accession EU126886) for PCV2 was used to 
al copy number in pooled fecal samples; it was reported as copy number of  
 feces. The assay d to detect the current genotypes CV2 with 
in PCV2. Each extracted fecal 
and ative PCR ell plate contained smid 
urve in duplicate (ran -1 copies per well). Each plate 
icate val e averaged for al s 
nly when the difference between samples had a threshold cycle (Ct) value <1. If the Ct was >1, 
V2 per gram of homogenized feces. 
 
 
m
is
 Buffer, QIAamp DNA stool m
ly, prior to thawing. NA extraction 
modifications included .5 mL, inste
sample in stool ted DNA w
was performed. 
A prev 48), quantitat
PCR assay and curve (Genban
determine the vir
PCV2 in 1 g of was develope of P
equal efficiency; it does not differentiate between genotypes with
sample was tested in duplicate,  each quantit 96-w a pla
standard c ge 6.60 × 106 to 6.60 × 10
contained a negative control in duplicate, and dupl ues wer l sample
o
the extracted sample was repeated in duplicate. A cutoff value representing the detection 
limit of the assay was extrapolated from a plasmid standard curve, as previously described (148), 
and was set at 1 to 10 copies of PC
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6.3.3 
 a commercial 
atistics package (Statistix 8; Analytical Software, Tallahassee, FL, USA). The box and whisker 
lots in Figure 6.1 were created by using a separate statistics package (Stata 10; StataCorp LP; 
ollege Station, TX, USA). 
.4 Results
Statistical Analysis 
Since PCV2-shedding in feces was non-normally distributed, nonparametric tests were 
used for statistical comparison. The Wilcoxon Rank Sum Test was used to compare production 
stage group median PCV2-shedding between PCVD-nonaffected and PCVD-affected pigs. To 
control for multiple comparisons, a Bonferroni correction was applied to adjust the P-value at 
which comparisons were considered significantly different (P=0.005 for 10 comparisons).  
Within each barn, the median PCV2-shedding in feces for the production stage with the highest 
observed load was compared with that of the preceding production stage, using a Wilcoxon Rank 
Sum Test. For groups where there was an observed difference in the presence of pigs not 
shedding detectable virus in the feces, the numbers of shedders and non-shedders were 
compared, using a Fisher’s Exact Test. Statistical analysis was performed, using
st
p
C
6  
Since an interaction was present between production stage and barn with respect to the 
CV2 shed in feces, separate barn comparisons were made for each production stage. The 
bserved median PCV2 shed in feces was higher in the PCVD-affected herd compared with the 
CVD-nonaffected herd in the NW, NU, PG, GR, S ≤2, S ≥3, and B stages, but it was 
gnificantly higher only in the three youngest (NW, NU, PG) stages (P<0.001; Figure 6.1). 
onversely, the observed median PCV2 shed in feces was higher in the PCVD-nonaffected herd 
 the FIN, VG, and BG stages, but it was significantly higher only in the VG stage (P=0.0002; 
igure 6.1). The highest observed PCV2 shed in feces occurred in a later production stage in the 
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PCVD-nonaffected herd (GR) than in the PCVD-affected herd (NU), and the PCV2 shed was 
gnificantly higher than in the immediately preceding stages (P≤0.0001) for each herd. For most 
roduction stages, there was detectable viral DNA in all or almost all fecal samples. More sows 
 ≤2 and S ≥3) in the PCVD-nonaffected herd did not shed PCV2 in feces, or the level of 
CV2-shedding was below the detection limit of the quantitative PCR assay used in this study, 
hen compared with the PCVD-affected herd (Figure 6.2). However, this difference was 
gnificant only for the older sow group (S ≥3; P=0.001). 
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Figure 6.1: Box and whisker plots of PCV2 shed in feces by pen quantified by real-time P
(approximately 10 pooled pens per stage; range=7 to 14) for each production stage in a PCV
nonaffected and a PCVD-affected commercial swine herd. Production stages significantly 
different between barns were NW, NU, and PG (P<0.001), and VG (P=0.0002). (Horizontal 
lines represent the median; upper and lower edges of the boxes represent the 75th and 2
percentile, respectively; and lines (whiskers) attached to the top and bottom of the boxes ext
to the maximum and minimum data points that are up to 1.5 times the interquartile range (1.5 
IQR) from the 75th or 25th percentile, respectively. Outliers are data points that are more than 
1.5 IQR from either the 25th or 75th percentile and are denoted as ‘x’).  
NW=newly weaned; NU=nursery; PG=pregrower; GR=grower; FIN=finisher; VG=virg
BG=bred gilt; S ≤2=lactating sow parity ≤2;  S ≥3=lactating sow parity S ≥3; B=boar. 
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Figure 6.2: 
real-tim
The percent of pooled fecal samples that were negative for PCV2 by quantitative 
e PCR for each production stage in a PCVD-nonaffected and a PCVD-affected 
commercial swine herd. The number of sows that were negative for PCV2 in feces of the total 
tested is shown. Production stage significantly different between barns (S ≥3; P=0.001) is 
denoted with an asterisk ( * ).  
NW=newly weaned; NU=nursery; PG=pregrower; GR=grower; FIN=finisher; VG=virgin gilt; 
BG=bred gilt; S ≤2=lactating sow parity ≤2;  S ≥3=lactating sow parity S ≥3; B=boar. 
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6.5 Discussion 
This study evaluated the PCV2 shed in pig feces among production stages in a PCVD-
affected compared with a PCVD-nonaffected herd, using quantitative real-time PCR. Quantities 
of PCV2 DNA were significantly higher in younger production stages in the PCVD-affected 
herd (NW, NU, and PG) than in the PCVD-nonaffected herd; however, gestational sows and 
boars (BG, S, and B) had similar median PCV2 shed in feces between herds. Possible 
explanations for the differences in viral shedding profiles of young pigs between these herds may 
e associated with early PCV2 exposure or the infectious dose, or both, to which piglets are 
xposed in the farrowing crate by sows shedding PCV2. Sows shedding PCV2 in feces into the 
rrounding environment may expose piglets to the virus via the oronasal route (207). In 
ddition, vertical transmission of PCV2 from the sow to piglets can occur in utero (151;228), and 
CV2 is shed in colostrum (206). It is feasible that sows with a higher systemic PCV2 viral load 
may expose piglets to a higher infectious dose of PCV2, either in utero or during the neonatal 
period, but this has not been reported. 
Maternal Ab protection provided to piglets in the neonatal period may be extremely 
variable among sows (149;182). The amount or concentration and the virus neutralizing 
capability of the Ab provided to piglets from the sow affect both the duration of immunity in the 
young pig and the ability to reduce or prevent viral replication. Both of these conditions 
contribute to effectively reduce the PCV2 viral load in the piglet; however, the immune status of 
the sows or their respective piglets in this study was not known. Passive Ab provide protection in 
early life (NW, NU, and, possibly, PG); when maternal Ab wane, PCV2 viremia is detected 
(145). The report that the amount of PCV2 shed in feces is correlated with the systemic or tissue 
PCV2 viral load (200) supports the observation that a significant increase in the PCV2 shed in 
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feces occurred in the GR stage in the PCVD-nonaffected herd, after protective maternal Ab had 
waned. This suggests that sufficient protection was afforded to the piglet until degradation of 
maternal Ab at approximately 10 weeks of age, at which time, PCV2-shedding in feces was 
observed to increase significantly. It can only be postulated that passive protection afforded to 
the piglet by maternal Ab, the dose of PCV2 that piglets are exposed to in early life, or both 
contribute to the resulting viral load in the pig once it reaches the GR stage.  
In the PCVD-affected herd, the PCV2 shed in feces was highest in the NU stage. The 
PCV2-specific immunity of the sows, or their respective progeny, was not tested in this study; 
however, by pooling fecal samples representing each production stage within a PCVD-affected 
and a PCVD-nonaffected herd, it was determined that significantly more sows in the PCVD-
affected herd shed detectable levels of PCV2 in their feces. This observation suggests that sows 
shedding PCV2 in their feces may contribute to the earlier exposure and infection of piglets in 
the farrowing crate, as seen by the PCV2 fecal-shedding profile of young pigs in the PCVD-
ffected herd (Figure 6.1). The corollary is that the majority of sows in a PCVD-nonaffected 
eces from 
dividual animals, are underway. Quantifying PCV2 in the feces of piglets from sows with 
nown immune and fecal-shedding status would further elucidate this association, and piglets 
rom individual sows in a population should be followed through NW, NU, PG, GR, and FIN 
a
herd may not shed detectable levels of PCV2 in their feces; therefore, piglet exposure is reduced 
and delayed until the mixing of pigs in the NU stage. A significant increase in PCV2 DNA is 
then observed in the feces of pigs in the GR stage, as a result of this delay in exposure in the 
PCVD-nonaffected herd. 
To substantiate the effect of sows shedding PCV2 in their feces on piglets in the 
arrowing crate, future studies, using serially collected samples of blood and ff
in
k
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production stages. Additionally, it is not known if pen density (Table 6.2) and the resulting 
crease in the mixing of pigs contributed to the increase in PCV2 fecal-shedding in younger 
pigs in the PCVD-affected herd in this study. Future studies should include herds consisting of 
similar pen densities by production stage of the pigs. The PCV2 shed in feces across production 
stages in PCVD-affected and PCVD-nonaffected herds have not been reported previously. Based 
on the shedding profile between pigs in a PCVD-affected and a PCVD-nonaffected herd, 
quantitative real-time PCR of PCV2 in feces may be a useful tool to evaluate viral load in pigs. 
Future applications for PCV2 quantitative PCR in pig feces may include measures for vaccine 
efficacy, treatment of PCVD, or changes in production and management practices. More pigs, 
particularly lactating sows, in the PCVD-nonaffected herd had no PCV2 DNA detected in feces 
by quantitative real-time PCR when compared with the PCVD-affected herd. As a result, there 
may be an association between the presence of PCV2 in the feces of lactating sows, increased 
quantity of the virus in the feces of younger pigs, and mortality in PCVD-affected herds. Further 
study with serial sampling in PCVD-affected and PCVD-nonaffected farms is required to 
elucidate this potential relationship.  
in
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CHAPTER 7 
REDUCTION IN MORTALITY BY TRANSDERMAL VACCINATION OF PIGLETS 
WITH ISCOM MATRIX Q-ADJUVANTED PCV2 VIRUS-LIKE PARTICLES IN A 
PCVD-AFFECTED COMMERCIAL SWINE HERD 
Submitted to: Can J Vet Res. 2011. McIntosh KA, Parker SE, Andreoni C, Harding JCS, 
Charreyre C, Fossum C, Lövgren K, Ellis JA. 
This research was conducted in 2006 to 2007. 
 
 
7.1 Abstract 
Our objective was to determine the efficacy of a novel transdermal ISCOM technology 
based PCV2 virus-like particle (VLP) vaccine candidate administered at one and three weeks of 
age. Fifty-four pigs (vaccinates (n=27); non-vaccinated controls (n=27)) with variable levels of 
maternally-derived PCV2-specific antibodies (MDAb) (high (hiMDAb) versus low (loMDAb)) 
in a PCVD-affected farm were assessed for PCV2-specific Ab levels by cELISA, PCV2 DNA 
concentration in serum and feces by quantitative PCR, mortality, and average daily gain (ADG) 
from 1 to 18 weeks of age. A significant reduction in mortality (P=0.05) was observed. PCV2 
DNA concentration in serum was lower in the vaccinated pigs at 9 and 11 weeks of age (P=0.003 
and 0.01, respectively). In the vaccinates (both hiMDAb and loMDAb groups) at nine weeks of 
age had a higher Ab response to the challenge, while the non-vaccinated controls (both hiMDAb 
and loMDAb groups) had a significantly reduced Ab response in comparison. During this period 
of 9 to 11 weeks of age, the loMDAb CTRL became susceptible to PCVD. PCV2-specific Ab in 
serum was significantly higher in vaccinated pigs at the onset of PCVD-related mortality 
(P=0.001); however, no significant difference was observed in the PCV2 DNA concentration 
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shed in feces, or in ADG. This study is the first report of the use of an ISCOM matrix (Matrix Q) 
mixed with PCV2 VLP protein administered transdermally for the prevention of PCVD in swine. 
7.2 Introduction 
 Isolated in 1998 (59), PCV2 is a small non-enveloped single stranded circular DNA virus 
that is the etiological agent of PMWS (9). First recognized in the early to mid 1990’s, PMWS 
typically affects pigs from 7 to 15 weeks of age with jaundice, pallor, dyspnea, diarrhea, 
enlarge
ns 
), 
iae (180), immune stimulation (114), early weaning (193), and poor 
produc
d lymph nodes, wasting, and increased postweaning mortality (47;88). A diagnosis of 
PMWS is based on the presence of clinical signs, in addition to characteristic histological lesio
associated with multiple organs and/or lymphatic tissue, and the detection of PCV2-specific 
antigen or DNA in the affected tissues (201).  
PCV2 is associated with additional disease syndromes including porcine dermatitis and 
nephropathy syndrome (PDNS) (151), porcine respiratory disease complex (PRDC) (105
reproductive disorders (166), and abortion (228). Recently, diseases associated with PCV2 
infection were collectively termed porcine circovirus diseases (PCVD) (5) or porcine circovirus-
associated disease (PCVAD) (17). It is recognized that both infectious and non-infectious 
cofactors contribute to the exacerbation of PCVD in pigs and these may include porcine 
parvovirus (PPV) (115), porcine reproductive and respiratory syndrome virus (PRRSV) (10), 
Mycoplasma hyopneumon
tion practices (194).  
In 2004, an increase in the severity of PCVD was observed in Canada and was proposed 
to be associated with a particular genotype of PCV2, described as PCV2b (71). This proposition 
that a specific genotype of PCV2 is related to more severe PCVD remains controversial, as 
subsequent research has both supported (77;123) and contradicted (13;179) this theory. 
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However, it is recognized that PCV2 is ubiquitous in swine populations globally, and PCVD 
contributes to excessive animal and monetary losses in the swine industry. 
The PCV2 viral load or DNA concentration in tissues has been reported to be associated 
with the severity of PCVD in swine (91;112) and recently, the quantification of PCV2 DNA in 
feces was found to be significantly higher in young pigs (3 to 12 weeks of age) in a PCVD-
affected herd when compared with an unaffected herd (147). Additionally, PCV2 DNA 
concentration in serum, as measured by quantitative real-time PCR (qPCR), is associated with 
PCVD severity (29). Therefore, PCV2 DNA concentration in serum and feces may be an 
appropriate and non-invasive way to determine the efficacy and ability of a vaccine against 
PCV2 to reduce PCV2 infection, replication, and ultimately death due to PCVD in swine. 
Due to the ubiquitous nature of PCV2, implementing vaccination protocols may be the 
best solution for the reduction and prevention of PCVD. Commercial vaccines against PCV2 
have been effective in reducing the viral load, morbidity, and/or mortality associated with PCVD 
in experimental (173) and natural (110;203) PCV2 infections. Additionally, several experimental 
PCV2 vaccines have improved the immunity to PCV2 infection in swine (23;62;65). Protocol 
tion of dams, their offspring, or both (187); however, MDAb may 
during the first three weeks of life. To circumvent the potential effects of MDAb, 
rget antigen (such as VLP, as described in this study) can be formulated with an ISCOM 
chnology based Matrix Q adjuvant. Traditional ISCOMs have successfully been used in 
nimals with MDAb (156). Furthermore, inactivated adjuvanted vaccines may have a propensity 
ward Ab (Th2) responses, as opposed to a more balanced Ab (Th2) and cell-mediated (Th1) 
sponse which is optimal for protection against viral infections and can be achieved by the use 
variations include the vaccina
(69) or may not (175) interfere with a piglet’s ability to mount their own response to PCV2 
vaccination 
ta
te
a
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of an ISCOM technology based adjuvant (157). The objectives of this study were as follows: 1) 
to determine if rectal temperature, injection site reactivity, and the activity level of 1 week old 
conventional piglets were adversely affected by varied doses of Matrix Q injected 
subcutaneously; 2) determine if a novel Matrix Q PCV2 VLP vaccine administered 
transdermally could successfully prime young pigs to PCV2 in the presence of PCV2 MDAb; 3) 
use four non-invasive outcome measures of PCV2-specific Ab level in serum, PCV2 DNA 
concentration in serum and feces, and average daily gain (ADG) to determine the efficacy of the 
vaccine; and 4) to determine if the use of the novel vaccine reduced mortality caused by PCVD 
rm experiencing elevated mortality associated with PCVD. 
7.3 
in a commercial fa
Materials and Methods 
7.3.1 Matrix Q testing for adverse reactions 
The potential for adverse reactions of the Matrix Q (the ISCOM matrix particles with no 
added protein) used in this study was tested by the subcutaneous injection of variable doses of 
the matrix into seven day old piglets. Piglets were injected with either 75 µg (n=3), 100 µg 
(n=3), or 150 µg (n=3) of the Matrix Q diluted in sterilized 0.01 M phosphate buffered saline 
(PBS) to a final volume of 200 µL using a 1 mL-25 gauge needle. A single injection was 
administered subcutaneously 1 cm off the dorsal midline between the shoulders and piglets were 
observed seven times over a period of 30 hours for rectal temperature, injection site reactivity 
(swelling, redness, or pain), and activity level (active or lethargic). Piglets used for the testing of 
Matrix Q adverse reactions were not used in the vaccine study described here. 
7.3.2 Animals  
Fifty-four PIC-crossbred piglets (six piglets from each of nine litters; 27 male; 27 female) 
were grouped by litter and matched by weight within each litter and randomly assigned to either 
 91
a vaccinate group (VX) or a non-vaccinated control (CTRL) group. Within litter, each of the six 
piglets were assigned to a weight classification of small, medium, or large; therefore, two piglets 
per weight classification per litter could be randomized into either treatment group (VX or 
ccur. The piglets remained with their biological or 
fostered
. pomona using a commercially available product (FarrowSure B; 
Pfizer 
CTRL), and ear-tagged. Litter and weight at one week of age were considered the most 
important variables biasing the outcome measures of vaccine efficacy, and the randomization 
resulted in 14 females and 13 males in the CTRL and 13 females and 14 males in the VX. The 
median weight for VX and CTRL at one week of age was 2.5 +/- 0.56 kg and 2.5 +/- 0.76 kg, 
respectively. Pigs used in this study were born between October 17th and 20th, 2006, were not 
segregated from the barn population, but moved through the production stages and mixed with 
other similarly aged pigs, as would normally o
 dam in solid partitioned farrowing crates from birth and until three weeks of age, moved 
to the nursery at three weeks and stayed there until 11 weeks of age, and then into the grow-
finish rooms from 11 weeks of age and until dispatch for slaughter.  
The pigs were housed in a 600 sow commercial swine farrow-to-finish facility in 
Saskatchewan practicing high-biosecurity procedures. Except as described in this study, 
commercial or experimental porcine circovirus type 2 vaccines were not used in this facility prior 
to or during this study. Sows were routinely vaccinated for porcine parvovirus (PPV), 
Erysipelothrix rhusiopathiae, Leptospira bratislava, L. canicola, L. grippotyphosa, L. hardjo, L. 
icterohaemorrhagiae, and L
Animal Health, Kirkland, QC, Canada). The facility experienced a 10.1% postweaning 
mortality in the two months preceding this study and 40% of the postweaning mortality was 
attributed to PCVD based on the clinical observations (unthriftiness, dyspnea, and diarrhea) by 
farm technicians. Additionally, the presence of characteristic lymphoid lesions of PCVD and 
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typical PCV2 immunohistological lesions based on PCV2 capsid staining were observed in the 
tissues of selected pigs submitted for diagnostics (Prairie Diagnostic Services, Saskatoon, SK, 
Canada
 Serial 
serum s
 
). All procedures were conducted in accordance with the University of Saskatchewan’s 
Committee for Animal Care and Supply (permit #20060004).  
7.3.3 Sample collection 
All blood samples were collected via the jugular vein into individual sterile serum tubes 
and the clotted blood was transported from the barn to the Western College of Veterinary 
Medicine in a chilled and insulated box and stored at 4ºC for 18 hours. Serum was then removed 
after centrifugation at 500 g × 15 minutes at 4ºC and aliquots from individual pigs were stored in 
sterile 1.5 mL microcentrifuge tubes at -70ºC until DNA extraction or ELISA analysis.
amples were collected at 1, 3, 7, 9, 11, 13, and 18 weeks of age. This collection schedule 
was based on the results of a previously described study that used conventional PCR and an 
ELISA to detect PCV2 in a naturally-infected herd (145). Rectal fecal samples were collected at 
3, 7, 9, 11, 13, and 18 weeks from individual pigs into sterile 2.0 mL microcentrifuge tubes, 
transported as described above, and stored at -70ºC until analyses. Fecal samples were not 
collected at one week of age, as piglets were too small to retrieve a rectal sample. Sporadically, 
rectal fecal samples were not collected from all pigs at each time point, as a sample may not have 
been available. Pigs were weighed at 1 and 18 weeks of age and the ADG of each pig calculated.   
7.3.4 Matrix Q  preparation 
The adjuvant component Matrix Q (AbISCO-300) was prepared according to standard 
procedures and supplied by Isconova AB, Uppsala, Sweden. In brief, it was prepared from 
semipurified saponins originating from Quillaja saponaria Molina and mixed with detergent 
solubilized cholesterol (C8503, Sigma-Aldrich, USA) and egg derived phosphatidyl choline (E-
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PC S; Lipoid GmbH Products, Germany). After 6 to 18 hours of incubation at room temperature, 
matrix particles were formed by removal of the detergent by ultrafiltration. The final product was 
filtered through a 0.22 µm filter and the saponin concentration was 3.12 mg/mL, as determined 
by reverse phase high performance liquid chromatography (RP-HPLC). All components of 
animal origin used for the process were issued a TSE certificate and the matrix was shipped from 
Sweden to the Western College of Veterinary Medicine in Saskatoon, Canada and stored at 4ºC. 
The matrix preparation was dissolved to a final concentration of 75 µg in 200 µL of either PCV2 
VLPs (VX) or 0.01 M PBS (CTRL).  
7.3.5 PCV2 VLP preparation 
Sf9 cells cultured in spinner flasks were infected with recombinant baculovirus 
s  a multiplicity of infection of one and at a cell 
concen
as 50 mg/mL, as 
nchoninic Acid (BCA) Protein Assay. 
 
expres ing the complete ORF2 gene of PCV2 at
tration of 2 × 106 cells/mL. Cell culture was harvested at 72 hours post-infection. The cell 
culture was centrifuged at 4000 × g for 10 minutes at 4°C and VLPs extracted from the resulting 
cell pellet. Briefly, cells were lysed in lysis buffer (0.2% NP40, 50mM tris-HCl, 200 mM NaCl), 
and the resulting suspension clarified for 15 minutes at 10,000 × g. The supernatant containing 
the VLPs was further concentrated through a 30% sucrose cushion by ultracentrifugation at 
100,000 g × 3 hours at 4°C. The resulting VLP pellet was resuspended in PBS and PCV2 capsid 
expression was confirmed by western blot. The characteristic morphology of the PCV2-like 
virions and the integrity of the VLPs were confirmed by electronic microscopy and the amount 
of VLPs was estimated to be 1012 VLPs/mL. Total protein quantification w
estimated by a Bici
 
 94
7.3.6 Vaccination 
Piglets were vaccinated at one and three weeks of age using a transdermal needle-free 
injection device (Biojector 2000; Bioject Medical Technologies, Tualatin, Oregon, USA). A total 
of 200 µL was injected into the neck of each piglet and contained either 75 µg of Matrix Q and 
1.66 × 1011 VLPs (or 8.3 mg of total VLP protein) for the VX or 75 µg of Matrix Q only made 
up to 200 µL with sterile 0.01 M PBS for the CTRL. Blood was collected from each piglet 
immediately prior to each vaccination at one and three weeks of age. 
7.3.7 Postmortem analyses 
The carcasses of pigs that were part of this study that either died or were euthanized 
because moribund between 1 and 18 weeks of age were submitted for necropsy and 
histopathology (Prairie Diagnostic Services, Saskatoon, SK, Canada). Additionally, 13 tissue 
samples (inguinal lymph node, mesenteric lymph node, spleen, liver, kidney, ileal Peyer’s patch, 
thymus, lung, bronchial lymph node, heart, tonsil, and gluteal muscle) were collected separately 
at the time of necropsy from each pig and submitted for IHC for PCV2 capsid antigen (Prairie 
Diagnostic Services, Saskatoon, SK, Canada). Pathologists and technicians were blinded from 
the treatment group of the animals submitted for necropsy, histopathology, bacteriology, and 
IHC, and a cause of death was ascertained based on the pathologic and bacteriologic results. 
7.3.8 DNA extraction 
Serum samples (n=345) were thawed and DNA extracted using a commercial DNA 
extraction kit (DNeasy tissue kit; Qiagen Inc., Mississauga, ON, Canada), as previously 
described (148). Fecal samples (n=286) were removed from storage, immediately weighed to 
allow for quantification per gram of feces, and DNA extracted using a commercial DNA 
extraction kit (Qiamp DNA stool mini kit; Qiagen, Mississauga, ON, Canada), as previously 
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described (148). One template blank or negative control sample was extracted with every set of 
24 samples. Extracted negative control, serum, and fecal samples were stored at -70ºC until PCR 
analysis. 
7.3.9 Quantitative real-time PCR 
A previously described qPCR assay (148) was used to determine the amount of PCV2 
virus p
omes) was adjusted mathematically by taking into consideration 
the star
resent in the serum and feces of both VX and CTRL for all samples collected during this 
study. The qPCR assay applied targets the highly conserved Rep gene (ORF1) and does not 
differentiate between genotypes PCV2a and PCV2b of the virus. Primers, reaction mix, template 
volume, cycling conditions, dilutions, plasmid standard curve development and extrapolation, 
and equipment were as previously described (148). All extracted samples and negative controls 
were tested in duplicate on 96-well plates and included a plasmid standard curve on each plate in 
duplicate over a range of 6.6 × 108 to 6.6 × 10-1 copies of plasmid per reaction (or 2.2 × 1011 to 
2.2 × 102 copies per mL). A dissociation curve or melting temperature of between 77.1ºC and 
77.8ºC was observed for each PCV2 positive sample and a cutoff value corresponding to a 
threshold cycle (Ct) of 35.47 (6.6 copies per reaction or 2.2 × 103 copies per mL) was applied, as 
previously described (148). Duplicate samples with Ct values >1 were repeated in duplicate. 
Individual sample results were reported as an average of the duplicate. All serum samples were 
measured (µL) and fecal samples weighed (mg) prior to DNA extraction. The amount of PCV2 
virus (copy number of PCV2 gen
ting volume or weight of each individual sample, the final volume of elution, and the 
volume of template added to the real-time PCR reaction mix, as previously described (148). 
Serum and fecal samples were expressed as the number of copies of PCV2 genomes in the 
original sample per 1 mL or 1 g, respectively.  
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 7.3.10 Competitive ELISA 
An aliquot from the same serum samples (n=345) used for DNA extraction was used to 
measure PCV2-specific Ab level by cELISA. The percent inhibition (PI) of a sample was 
determined using a previously described cELISA (225) with modifications (145). One additional 
adaptation was made where each original serum sample was diluted a further 1:2 to a final 
concentration of 1:500 in each sample well. Samples were tested in duplicate on 96-well 
microtiter plates and results reported as an average of the duplicate. Each 96-well plate included 
gative sample, and a no serum blank control. 
7.3.11 
he cutoff point for hiMDAb (≥90.0 PI) 
ersus loMDAb (<90.0 PI). Figures presented represent the effect of VX versus CTRL within 
a pig serum PCV2-positive and –ne
Statistical Analyses 
PCV2-specific MDAb can affect vaccine performance in young pigs (69); therefore, 
PCV2-specific Ab measured at one week of age were taken to be representative of MDAb. The 
effect of MDAb on the relationship between vaccine status and outcome measures was 
accounted for in the analysis. Because the period from 9 to 11 weeks of age was identified as a 
biologically important period in this study due to the onset of PCVD-related mortality and 
increased variability in PCV2-specific Ab and PCV2 DNA concentration in serum, analyses and 
discussion were primarily limited to this period. The relationship between MDAb (measured at 
one week of age) and Ab (measured at nine weeks of age and concomitant with the onset of 
PCVD-related mortality) was not linear (Figure 1), and animals were categorized as having 
either loMDAb or hiMDAb for the analysis. The median PI or Ab level at one week of age (prior 
to vaccination) for all animals was 90.0 and was used as t
v
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MDAb status group; however, statistical analysis was also performed for VX versus CTRL, 
irrespective of MDAb (figures and data not shown). 
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(% inhibition) from non-vaccinated control (CTRL) versus vaccinated (VX) pigs in a PCVD-
specific antibodies measured at one week of age and determined to be 90.0% inhibition. The 
antibodies (loMDAb) (<90.0%) versus high PCV2-specific maternally-derived antibodies 
 
 
 
 
Figure 7.1: Scatter plot for PCV2-specific antibodies in serum measured by competitive ELISA 
affected barn at one versus nine weeks of age. Dashed reference line is the median PCV2-
median value of 90.0% represents the cutoff value for low PCV2-specific maternally-derived 
(hiMDAb) (≥90.0%). 
(Dashed reference line – Median week 1 PCV2-specific antibody 90.0) 
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MDAb status group (hiMDAb and loMDAb) 
easures: PCV2-specific Ab levels in serum; PCV2 DNA 
concentratio
t difference 
re P≤0.05/k comparisons, where multiple comparisons were 
made for an outcom
VX and CTRL, and VX and CTRL within 
were compared based on five outcome m
n in serum; PCV2 DNA concentration in feces; mortality; and ADG. Continuous 
outcomes (PCV2-specific Ab in serum, copies of PCV2 in serum and feces, and ADG) were 
compared using the Student’s t-test for the comparison of two groups or a two-way Analysis of 
Variance (ANOVA) where multiple factors were considered. Results were considered significant 
where P≤0.05. 
      For outcomes that were not normally distributed, a Wilcoxon Rank-Sum Test was used. 
The Bonferroni correction was applied to adjust for the P value at which a significan
was detected (P was significant whe
e) (165). P values were rounded up to two decimal places.  
      Proportional mortality due to PCVD was compared using the Fisher’s Exact Test and was 
significant where P≤0.05. Pigs that died or were euthanized from causes other than PCVD (non-
PCVD related deaths such as: meningoencephalitis (n=2); septicemia (n=1); bloated abdomen 
(n=1)) were not included in the comparison of survival between VX and CTRL (Table 1). ADG 
was calculated from the difference in weight between the beginning and end of the study (1 and 
18 weeks of age; duration=124 days) and divided by the duration.       
      Statistical analysis was performed, and scatter plots and line graphs were created using a 
commercial statistics package (Stata 11; StataCorp LP, College Station, Texas, USA).  
 
 
  
 
Table 7.1: Results of pathologic and bacteriologic assessment of pigs vaccinated with an immune stimulating complex (ISCOM) 
Matrix Q adjuvanted porcine circovirus type 2 (PCV2) virus-like particle (VLP) transdermal vaccine that either died or were 
euthanized between 1 and 18 weeks of age. 
 
Pig 
 
Groupa 
 
Antibody 
Groupb 
Agec 
 
Cause of Deathd, e
 Necropsy Observations Associated with the Pathological and Histological Diagnosis V
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of PC D 
     Gross Pathology Lymph Node Pathology Immunohistoc strhemi y 
11 CTRL hiMDAb 2 Bloated abdomenf    
13 VX hiMDAb 9 Meningoencephalitis  (S. suis) 
   
53 CTRL hiMDAb 9 Meningoencephalitis (S. suis) 
   
38 CTRL loMDAb 9 PCVD 
small, long-haired, wasted, pale 
kidneys, depleted thymus, 
generalized enlargement of LN 
depleted follicles, epithelioid  
macrophage infiltration 
abundant in tons
intestine, kidney 
ils, 
34 VX hiMDAb 10 Septicemia (S. suis)    
23 CTRL loMDAb 10 PCVD 
small, long-haired, wasted, 
depleted thymus, generalized 
enlargement of LN 
lymphoid atrophy, scattered 
multinucleated cells 
abundant in tons
intestine  
ils, lung, 
20 CTRL loMDAb 11 PCVD 
small, wasted, pale kidneys, small 
cobblestone liver, generalized 
enlargement of LN 
pathognomonic intracellular 
inclusions typical of PCV2 
infection 
abundant in tons un
intestine, kidney 
ils,  l g, 
, 
47 CTRL loMDAb 11 PCVD 
small, long-haired, thin, depleted 
thymus, finely pink cobblestone 
lungs failed to collapse 
pathognomonic intracellular 
inclusions typical of PCV2 
infection 
abundant in tonsils, lung
intestine, kidney 
, 43 CTRL loMDAb 11 PCVD small, long-haired, wasted, generalized enlargement of LN 
characteristic lymphoid lesions 
of PCVD; lymphocyte depletion 
abundant in tonsils, lung
intestine 
 
 
a  Groups are vaccinated (VX) (n=27) or non-vaccinated controls (CTRL) (n=27). CTRL 
received ISCOM Matrix Q only which contained no PCV2 VLP protein. 
b  Antibody group includes the following designations based on the PCV2-specific antibody 
measured at 1 week of age by competitive ELISA and were considered representative of the 
PCV2-specific maternally-derived antibodies (MDAb) in serum: low maternally-derived 
antibodies (loMDAb; <90.0% inhibition) or high maternally-derived antibodies (hiMDAb; 
≥90.0% inhibition).    
c  Age in weeks. 
d  Streptococcus suis, as determined by bacteriologic assessment of brain, kidney, liver, lung, and 
spleen. 
e  Porcine circovirus disease (PCVD), as determined by the case definition (gross observations, 
lymphoid depletion, and PCV2 antigen associated with lesions in immunohistochemical 
analysis).  
f  Death was a result of a non-infectious cause (i.e. bloated abdomen or Atresia ani). 
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7.4 Results 
7.4.1 Matrix Q testing for adverse reactions 
      No adverse observations were made regarding the injection site or activity level of any 
piglet during the 30 hour period after injection with the Matrix Q. The expected normal rectal 
temperature of an unweaned piglet >24 hours of age is 39.2 ± 0.3ºC (212). Taking into 
consideration the baseline rectal temperature of each piglet (temperature prior to injection), only 
one piglet at 30 hours post-injection was observed to have a potential low grade fever of 39.6ºC 
mp
 VX than 
par
b at week nine (median 
.4.3 PCV2 DNA concentration in serum and feces 
    Overall, VX had significantly lower PCV2 DNA concentration in serum at 9 and 11 
weeks of age, (median copies per mL: VX=4.89 × 105, CTRL=2.31 × 106; P=0.003 and 
VX=1.12 × 105, CTRL=8.72 × 105; P=0.01, respectively) when compared with the CTRL. At 7, 
(a te erature greater than 0.3ºC above its baseline temperature and greater than 39.5ºC). This 
piglet received the lowest dose of Matrix Q of 75 µg. 
7.4.2 PCV2-specific antibody in serum 
      At nine weeks of age, overall Ab levels were significantly higher in the
com ed with the CTRL when not considering MDAb status (Wilcoxon Rank Sum Test; 
median Ab: VX=92.5%, CTRL=73.5%; P=0.001).      
      PCV2-specific Ab levels in serum for each treatment group and MDAb status over the 
sampling time period are shown in Figures 2a-2b. In the hiMDAb animals (Figure 2a), VX had 
higher Ab at week nine (median Ab=96%) than CTRL (median Ab=51%) (Wilcoxon Rank Sum 
Test; P=0.03). In the loMDAb pigs (Figure 2b), VX had higher A
Ab=94%) than CTRL (median Ab=84%) (Wilcoxon Rank Sum Test; P=0.002). Differences are 
considered significant at P≤0.03 after applying a Bonferroni correction for two comparisons. 
7
  
 103
13, and 1 e  of age, PCV2 DNA co entr n in rum as n ificantly different 
between VX and CTRL (P=0.2 =0.12 and P= , re ctiv . D es are considered 
significan P 01 after apply Bonf ni c io f com s.      
      PCV2 was not detected in the y  a nd three weeks of 
age (Figures 2c-2d). PCV2 DNA concentration in the hiMDAb pigs (Figure 2c) was not 
significantly different in serum ine wee Wilcoxin Rank 
Sum Test ). However, e loM  2
concentration at week nine (me opie 3 ) C edian copies per 
mL=3.87 × 10 Wilcoxon Rank Sum Te 0  red significant at 
P≤0.03 after applying a Bonferroni correction for two comparisons. 
      PCV2 DNA was not d t the fece n  by
(Figures 2 f CV2 DNA co ion c n if  between VX and 
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(a) 
 
 
(*)
Figures 7.2a – 7.2f: Line graphs presenting PCV2-specific antibody levels (% inhibition), as 
determined by competitive ELISA, in pigs with (a) high maternally-derived PCV2-specific 
ntibodies (hiMDAb) and (b) low maternally-derived PCV2-specific antibodies (loMDAb) in 
vaccinated (VX) versus non-vaccinated control (CTRL) groups. PCV2 viral load in serum and 
ces (copies of PCV2 DNA per mL or g, respectively), as determined by quantitative real-time 
PCR, in pigs with (c) and (e) high maternally-derived PCV2-specific antibodies (hiMDAb), and 
) and (f) low maternally-derived PCV2-specific antibodies (loMDAb) in vaccinated (VX) 
versus non-vaccinated control (CTRL) groups. Median values are plotted and whiskers attached 
 the top and bottom of the median extend to the maximum and minimum data points. Asterisks 
(*) denote comparisons between VX and CTRL that are statistically significant within MDAb 
roup.  
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(*)
Figures 7.2a – 7.2f: Line graphs presenting PCV2-specific antibody levels (% inhibition), as 
determined by competitive ELISA, in pigs with (a) high maternally-derived PCV2-specific 
antibodies (hiMDAb) and (b) low maternally-derived PCV2-specific antibodies (loMDAb) in 
vaccinated (VX) versus non-vaccinated control (CTRL) groups. PCV2 viral load in serum and 
feces (copies of PCV2 DNA per mL or g, respectively), as determined by quantitative real-time 
PCR, in pigs with (c) and (e) high maternally-derived PCV2-specific antibodies (hiMDAb), 
(d) and (f) low maternally-derived PCV2-specific antibodies (loMDAb) in vaccinated (V
and 
X) 
 es are plotted and whiskers attached 
um and minimum data points. Asterisks 
p. 
 
versus non-vaccinated control (CTRL) groups. Median valu
to the top and bottom of the median extend to the maxim
(*) denote comparisons between VX and CTRL that are statistically significant within MDAb 
grou  
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c) 
 
Figures 7.2a – 7.2f: Line graphs presenting PCV2-specific antibody levels (% inhibition), as 
etermined by competitive ELISA, in pigs with (a) high maternally-derived PCV2-specific 
antibodies (hiMDAb) and (b) low maternally-derived PCV2-specific antibodies (loMDAb) in 
accinated (VX) versus non-vaccinated control (CTRL) groups. PCV2 viral load in serum and 
feces (copies of PCV2 DNA per mL or g, respectively), as determined by quantitative real-time 
CR, in pigs with (c) and (e) high maternally-derived PCV2-specific antibodies (hiMDAb), and 
(d) and (f) low maternally-derived PCV2-specific antibodies (loMDAb) in vaccinated (VX) 
ersus non-vaccinated control (CTRL) groups. Median values are plotted and whiskers attached 
d bottom of the median extend to the maximum and minimum data points. Asterisks 
) denote comparisons between VX and CTRL that are statistically significant within MDAb 
group.  
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(d) 
 
(*)
Figures 7.2a – 7.2f: Line graphs presenting PCV2-specific antibody levels (% inhibition), as 
determined by competitive ELISA, in pigs with (a) high maternally-derived PCV2-specific 
antibodies (hiMDAb) and (b) low maternally-derived PCV2-specific antibodies (loMDAb) in 
vaccinated (VX) versus non-vaccinated control (CTRL) groups. PCV2 viral load in serum and 
feces (copies of PCV2 DNA per mL or g, respectively), as determined by quantitative real-time 
PCR, in pigs with (c) and (e) high maternally-derived PCV2-specific antibodies (hiMDAb), and 
(d) and (f) low maternally-derived PCV2-specific antibodies (loMDAb) in vaccinated (VX) 
versus non-vaccinated control (CTRL) groups. Median values are plotted and whiskers attached 
to the top and bottom of the median extend to the maximum and minimum data points. Asterisks 
(*) denote comparisons between VX and CTRL that are statistically significant within MDAb 
group.  
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(e) 
 
Figures 7.2a – 7.2f: Line graphs presenting PCV2-specific antibody levels (% inhibition), as 
 
determined by competitive ELISA, in pigs with (a) high maternally-derived PCV2-specific 
antibodies (hiMDAb) and (b) low maternally-derived PCV2-specific antibodies (loMDAb) in 
vaccinated (VX) versus non-vaccinated control (CTRL) groups. PCV2 viral load in serum and 
feces (copies of PCV2 DNA per mL or g, respectively), as determined by quantitative real-time 
PCR, in pigs with (c) and (e) high maternally-derived PCV2-specific antibodies (hiMDAb), and 
(d) and (f) low maternally-derived PCV2-specific antibodies (loMDAb) in vaccinated (VX) 
versus non-vaccinated control (CTRL) groups. Median values are plotted and whiskers attached 
to the top and bottom of the median extend to the maximum and minimum data points. Asterisks 
(*) denote comparisons between VX and CTRL that are statistically significant within MDAb 
group.  
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(f) 
 
Figures 7.2a – 7.2f: Line graphs presenting PCV2-specific antibody levels (% inhibition), as 
determined by competitive ELISA, in pigs with (a) high maternally-derived PCV2-specific 
antibodies (hiMDAb) and (b) low maternally-derived PCV2-specific antibodies (loMDAb) in 
vaccinated (VX) versus non-vaccinated control (CTRL) groups. PCV2 viral load in serum and 
feces (copies of PCV2 DNA per mL or g, respectively), as determined by quantitative real-time 
PCR, in pigs with (c) and (e) high maternally-derived PCV2-specific antibodies (hiMDAb), and 
(d) and (f) low maternally-derived PCV2-specific antibodies (loMDAb) in vaccinated (VX) 
versus non-vaccinated control (CTRL) groups. Median values are plotted and whiskers attached 
to the top and bottom of the median extend to the maximum and minimum data points. Asterisks 
(*) denote comparisons between VX and CTRL that are statistically significant within MDAb 
group.  
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7.4.4 Mortality and postmortem analyses 
      Mortality attributed to PCVD was significantly higher in CTRL (5/25) when compared 
with VX (0/25) (Fisher’s Exact Test; P=0.05) and all animals that died due to PCVD were in the 
loMDAb CTRL group. The primary clinical features observed by farm technicians in the PCVD-
affected pigs in this study prior to their death were wasting, dyspnea, and diarrhea and all PCVD-
related deaths occurred between 9 and 11 weeks of age. Nine of 54 pigs died or were euthanized 
during this study and of those deaths, eight were attributed to an infectious cause (five to PCVD; 
three to S. suis) and one to a congenital defect (Atresia ani). Details regarding the age, treatment 
group, MDAb status, cause of death, and the gross and microscopic observations associated with 
the case definition of PCVD of all deceased pigs during this study are summarized in Table 1. A 
PCVD diagnosis is based on the PCVD case definition of observed clinical and histological 
findings detailed by the American Association of Swine Veterinarians (AASV) (17). Those pigs 
with a diagnosis associated with Streptococcus suis infection were serotyped by slide 
agglutination with antiserum for those routinely typed (serotypes 1-9) (Prairie Diagnostic 
Services, Saskatoon, Canada) and all pigs were found to have a serotype outside that of 1 to 9. 
/- 0.0619 kg/day) (Two-sample t-test; P=0.10). In the CTRL, no difference between hiMDAb 
7.4.5 Average daily gain (ADG) 
      Between 1 and 18 weeks of age, the ADG in VX was 0.7630 +/- 0.0747 kg/day and in 
CTRL was 0.7465 +/- 0.0771 kg/day and no significant difference in ADG was found between 
groups (Two-sample t-test; P=0.47). However, within treatment group, MDAb status at one 
week of age appeared to have some effect on ADG. In VX, pigs with hiMDAb had a tendency 
toward a greater ADG (0.7868 +/- 0.0797 kg/day) when compared to pigs with loMDAb (0.7373 
+
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(0.7569 +/- 0.0881 kg/day) and loMDAb (0.7379 +/- 0.0639 kg/day) was detected (Two-sample 
t-test; P=0.52).  
7.5 Discussion  
      Commercial vaccines are now available for the prevention of PCV2-associated diseases 
or PCVD (110;173;203); however, the ability of these vaccines to ‘override’ maternal Ab and 
immunologically prime passively immune piglets has been conflicting (69;110). Our objective 
was to determine the efficacy of a novel vaccine candidate in a subset of pigs with variable levels 
of MDAb in a PCVD-affected farm by assessing PCV2-specific Ab levels, PCV2 DNA 
concentration in serum and feces, mortality, and ADG. This study is the first report of the use of 
an ISCOM technology based Matrix Q adjuvant mixed with PCV2 VLP protein administered 
transdermally for the prevention of PCVD in swine.  
      In VX, significantly higher PCV2-specific Ab in serum at nine weeks was observed. This 
elevated level of Ab may have assisted in preventing pigs in the VX from progressing to PCVD, 
as all deaths resulting from PCVD during this study occurred between 9 and 11 weeks of age. 
The occurrence of increased Ab levels at nine weeks of age when compared with seven weeks of 
and CTRL signifying a response to a considerable natural PCV2 challenge immediately 
ing and during the period of 9 to 11 weeks of age.  
age (Figures 2a-2b) suggests a PCV2 natural challenge occurred. Upon further investigation, the 
VX (both hiMDAb and loMDAb groups) at nine weeks of age had a higher Ab response to the 
challenge, while the CTRL (both hiMDAb and loMDAb groups) had a significantly reduced Ab 
response in comparison. During this period of 9 to 11 weeks of age, the loMDAb CTRL became 
susceptible to PCVD. After 11 weeks of age, Ab levels were high in the majority of pigs in both 
the VX 
preced
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      Due to the ability of ISCOMs to facilitate the priming of animals to antigen in the 
presence of MDAb (156), piglets were vaccinated at one and three weeks of age. Serum 
collected at one week of age and immediately prior to vaccination with the Matrix Q PCV2 VLP 
transdermal vaccine confirms that MDAb were present in the piglets based on the elevated PI of 
PCV2-specific Ab (Figure 1c). When considering MDAb and vaccine status at nine weeks of age 
(at the onset of PCVD-related deaths), hiMDAb CTRL pigs had a delayed Ab response to natural 
challenge (Figure 2a); however, none of these pigs succumbed to PCVD. A significant difference 
was observed in the Ab levels of loMDAb VX versus loMDAb CTRL pigs, where all pigs dying 
due to PCVD occurred in loMDAb CTRL group. It appears that vaccination and/or the presence 
of high MDAb may have protected the pigs from a PCVD-associated death. Additionally, the 
novel transdermal Matrix Q formulated PCV2 VLP vaccine appeared to have successfully 
primed young pigs in the presence of high MDAb, as there was a significantly higher Ab 
response at nine weeks of age in hiMDAb VX pigs when compared to hiMDAb CTRL (Figure 
2a). The observation that mortality due to PCVD was clustered in the loMDAb group implies 
that vaccination and hiMDAb are both equally protective, and that the benefit of Matrix Q/PCV2 
eks of age, observed median PCV2 DNA concentrations in sera were lower in the VX 
compared with the CTRL for all subsequent sampling periods, with the exception of the 
hiMDAb VX group at seven weeks of age (Figure 2c), although these differences were not 
VLP vaccination would be most apparent in pigs with loMDAb.  
      PCV2 DNA in serum was not detected in one and three week old piglets, suggesting that 
exposure to PCV2 in the farrowing crate or during gestation was minimal, MDAb were very 
effective at protecting piglets from PCV2 infection, and/or the PCV2 DNA concentration was 
below the detection limit of the assay. After the pigs were mixed and weaned into the nursery at 
three we
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statistically significant at all time periods (Figures 2c-2d). It is biologically important that the 
0 
e homogeneously shed in feces. In the previously described 
PCV2 shed in feces at any time point. 
VX had significantly lower PCV2 DNA in serum at 9 and 11 weeks of age when compared with 
CTRL, as this was the period of time where animal deaths attributed to PCVD occurred. When 
considering MDAb status, a significant difference in PCV2 DNA concentration in serum was 
only observed in the loMDAb group and the vaccine did not appear to decrease serum viral load 
in the hiMDAb group.  
      In a previous study, PCV2 DNA concentration in feces was found be significantly 
different between aged matched pigs in a PCVD-affected and a non-affected herd (147). 
Additionally, fecal swabs have been used by other researchers to determine the ability of a 
vaccine to reduce viral shedding, as a measure of vaccine efficacy (69). By contrast, PCV2 DNA 
concentration in feces did not differ between VX and CTRL in this study, irrespective of MDAb 
status. Our method included weighing individual rectal fecal samples and mathematically 
adjusting for the amount of feces tested, as opposed to a taking a rectal swab, which may contain 
a variable mass or volume of fecal material. PCV2 DNA quantification from a measured amount 
of feces is a more accurate method of quantifying DNA; however, a very small sample (<25
mg) is used and the virus may not b
study that determined significant differences between aged matched PCVD-affected and non-
affected pigs (147), samples were pooled and a 1 g sample was extracted for quantification, as 
opposed to the individual 250 mg samples tested in this study. It is possible that a larger sample 
of 1 g would offset the problem of a non-homogeneous sample in animals shedding higher levels 
of PCV2 in feces. Alternatively, although the Matrix Q PCV2 VLP vaccine significantly reduced 
PCV2 DNA concentration in serum at 9 and 11 weeks of age, it did not appear to reduce the 
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      The herd chosen for this study was experiencing elevated mortality due to PCVD. From 9 
and 11 weeks of age, five deaths attributed to PCVD occurred in the CTRL, exclusively the 
up. Importantly, no PCVD-associated deaths were observed in the VX for 
his study was not associated with serotypes 
loMDAb CTRL gro
the duration of the study (Table 1); thus, the Matrix Q PCV2 VLP vaccine was concluded to 
significantly reduce death due to PCVD.  
      S. suis infection was the only other infectious cause of death in the pigs and was 
responsible for the only two deaths in the VX and contributed to one death in the CTRL. S. suis 
is a common pathogen of pigs with meningitis being an important clinical presentation (75). S. 
suis serotype 2 is the most commonly isolated and frequently reported serotype from pigs with 
severe disease; however, more than 30 serotypes have been reported with variable disease 
association. The S. suis associated with mortality in t
1-9. 
      ADG is an important production measure and has been used to assist researchers in 
determining the benefits of vaccines against PCV2 infection (110). In this study, pigs with 
hiMDAb had numerically higher ADGs when compared with the loMDAb pigs within each 
treatment group; however, only within the VX did pigs with hiMDAb approach a significant 
improvement in ADG over the loMDAb pigs. A larger sample size may have elucidated this 
association, but it appears that the vaccine did not appreciably improve ADG. 
      Considerations for future studies testing vaccines based on ISCOM technology would 
include measures for cell-mediated immunity and IgG Ab isotypes. These parameters, albeit not 
the focus of this study, would have contributed to a greater understanding of the immune 
response invoked by the novel vaccine used here. 
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      In conclusion, our objectives were to assess the ability of a novel Matrix Q PCV2 VLP 
transdermal vaccine to successfully prime passively immune young pigs to PCV2 in a PCVD-
affected herd. Four non-invasive outcome measures along with mortality were used to assess the 
efficacy of the novel vaccine. The vaccine did not appear to reduce PCV2 DNA concentration in 
feces nor significantly improve ADG. However, a significant reduction in mortality and PCV2 
DNA concentration in serum in the VX was observed during 9 to 11 weeks of age, the period of 
time when CTRL pigs were dying due to PCVD and PCV2-specific Ab in serum was 
significantly higher in VX at the onset of PCVD-related mortality. High PCV2-specific MDAb 
was also associated with protection from PCVD-related death, as observed in the hiMDAb 
CTRL group and the vaccine was able to increase the PCV2-specific Ab response in the presence 
of elevated PCV2-specific MDAb, as evidenced in the hiMDAb VX group. However, viremia 
and fecal shedding were not significantly reduced in the hiMDAb VX group.   
      The benefit of the ISCOM vaccine was most evident in the loMDAb VX group, as these 
pigs were protected from a PCVD-related death, unlike the loMDAb CTRL group. In addition to 
a reduction in mortality, producers and veterinarians would expect a significant improvement in 
ADG and reduced viral shedding in feces prior to implementing a PCV2 vaccine in a PCVD-
affected herd. Therefore, these results indicate that the Matrix Q PCV2 VLP transdermal vaccine 
described here prevented PCVD-related death in the highest risk population (loMDAb group), 
but requires further modification in either ISCOM matrix dose or PCV2 VLP protein 
construction or concentration in future study. 
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CHAPTER 8 
 
 
 The studies that comprise this thesis are divergent; however, all sought to discover novel 
information using molecular techniques 
 
GENERAL DISCUSSION AND CONCLUSIONS 
 
for the detection or quantification of PCV2 in pigs 
 positive healthy herds and progressed to studies in PCVD-affected herds. This progression 
PCVD and were 
ction of PCV2 in serum by two PCR methods 
and the PCV2-specific Ab profile of pigs. The hypothesis – PCV2 is persistently present in the 
infected naturally with the virus. In addition, Ab detection and quantification was valuable to 
describe the passive transfer of PCV2-specific Ab to newborn piglets and to determine when pigs 
were challenged naturally with PCV2 in the barn setting. It is also important that pigs were not 
segregated from the population in any of our studies, but maintained in the barn according to 
previously established industry standard production practices. This allowed us to determine our 
results in a true barn scenario directly applicable to commercial farms. Our research began in 
PCV2
was shaped by the current events of the local swine industry in Saskatchewan.    
At the start of this research in 2002, PCVD was present in the herds in Saskatchewan, but 
was sporadic. PCVD was found to affect random individual pigs, but severe losses were rarely 
recognized at the herd level in most facilities with high biosecurity and proper production and 
management practices. This situation changed in approximately 2005. Previously healthy herds, 
albeit positive for PCV2, started to experience increased losses due to 
diagnosed at the herd level. This change in the PCV2 dynamic offered us an opportunity to study 
PCV2-fecal shedding in a healthy herd versus a PCVD-affected herd and to test a novel vaccine 
in a PCVD-affected herd that was not using commercial PCV2 vaccines. 
The first study was concerned with the dete
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seru of healthy pigs with high PCV2-specific Ab – was supported by testing pigs from five 
days of age and until slaughter at 156 days of age. We chose to collect blood samples at the 
beginning, midpoint, and end of each production stage in the barn for a total of eight successive 
collections. At the time, there were no published reports on the persistence of viremia and the Ab 
profiles of healthy pigs infected naturally with PCV2 that spanned all production stages.  
Three previously described assays were modified and used to complete the objectives for 
this study. A conventional nested and a non-nested PCR were used to detect PCV2 DNA in 
serum and a competitive ELISA measured the PCV2-specific Ab. The PCR assays had different 
detection limits and as expected, and a greater percentage of samples were positive for PCV2 
DNA in serum using the nested PCR method than with the non-nested assay. At the time of this 
study (2002) real-time quantitative PCR was not readily available.  
Piglets had very high levels of PCV2-specific Ab at five days of age; h
m 
owever, these Ab 
Based on the very high levels of PCV2-specific Ab at five days of age, passive transfer of 
CV2-specific Ab to the nursing piglets was successful; however, 10% and 15% of the pigs 
sted at 40 and 72 days of age had Ab levels below the cutoff for a positive result. This suggests 
declined after weaning at 40 days of age, and viremia was detected by both PCR methods at the 
subsequent blood collection (72 days of age). After PCV2 DNA was detected in the serum of the 
young pigs, the PCV2-specific Ab rose and remained elevated until the end of the study (156 
days of age). After the detection of PCV2 DNA in serum at 72 days of age, blood was collected 
at 107, 135, and 156 days of age and 45% of pigs were repeatedly positive in a minimum of two 
to a maximum of four samples. Based on these observations, several conclusions can be made 
about the passive transfer of PCV2-specific Ab and the young pig’s immune response to PCV2 
natural challenge.  
P
te
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a wide variation in the Ab passively transferred to the piglets. Viremia was not detected until 72 
days o
e nursery is concomitant with the waning of maternally-
erived PCV2-specific Ab and the subsequent detection of PCV2 DNA in serum. At 107 days of 
ge, following the detection of PCV2 DNA serum at 72 days of age, an observed increase in the 
CV2-specific Ab in the pigs occurred indicating a response to natural challenge with PCV2 in 
e nursery. This sequence of events suggests that PCV2 viremia is established when young pigs 
re mixed in the nursery.  
In conclusion, no correlations existed among measures of serum Ab, viremia, and the 
ffects of sex, breed, or age. However, the results from this study suggest that the PCV2-specific 
b in serum is not sufficient to prevent or resolve PCV2 viremia in pigs, as the virus persists in 
e presence of elevated levels of PCV2-specific Ab. Recent research confirms that it is not the 
resence of PCV2 in the serum, but the PCV2 viral load in serum and/or tissues of pigs that are 
ssociated with the disease potential or outcome of PCV2 infection (78;91;169;200). 
dditionally, a ‘litter effect’ has been described, where the sow PCV2 viral load and PCV2-
ecific Ab level in serum has a significant effect on litter mortality attributable to PCVD (31).  
To re-emphasize the importance of passively transferred maternally-derived PCV2-
ecific Ab in the protection of the piglet from PCVD, the commercial vaccine produced by 
erial is administered prior to farrowing (177). The vaccine produces elevated PCV2-specific 
f age, which suggests sufficient protection by maternal PCV2-specific Ab or other 
immunocellular protective mechanisms, or the absence of exposure to PCV2 in the first weeks of 
life. PCV2 is shed in the secretions of healthy PCV2-positive pigs (147;200), so it is likely that 
piglets were exposed to PCV2 in the farrowing crate by the sow. However, a PCV2 natural 
challenge may be greatest during the mixing and remixing of pigs in the nursery stage, after 
weaning. The mixing of pigs in th
d
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Ab in the serum of sows resulting in e sferred to the suckling piglets through 
colostrum. The elevated PCV2-specific Ab in e young pig due to vaccination of the sow is 
rotective against PCVD during the period of susceptibility following weaning (100). PCV2 
iral lo
 
 of the 43 boars tested. 
While 
levated Ab tran
th
p
v ad is kept below a level that contributes to the development of PCVD. 
 The second study was concerned with the detection of PCV2 in semen by nested PCR 
and the effects of the presence of the virus on semen quality. The hypothesis – PCV2 is 
intermittently-shed in the semen of healthy pigs and does not affect semen quality – was 
supported by testing 43 boars aged 33.9 to 149.3 weeks for a period of up to nine months. A total 
of 903 semen samples were collected representing Duroc, Landrace, Hamline, Large White 
maternal, Large White paternal and Meishan-synthetic breeds. Semen collection was dictated by 
commercial product demand; therefore, variation between collections and among boars occurred 
and could not be controlled. The average time between individual collections was 11 ± 8.9 days 
with a range of 2 to 81 days.    
At the time, two studies with a focus on the detection of PCV2 in semen were published. 
PCV2 had been detected in semen from boars infected naturally with the virus, but the shedding 
pattern and duration were not determined (108). In another study, PCV2 DNA was detected 
intermittently in semen from day 5 to 47 postinfection in boars infected experimentally with 
PCV2 (119). However, there was a lack of information regarding the long-term shedding 
patterns of PCV2 in semen from naturally-infected boars, and there were no reports regarding the 
potential effects of the presence of PCV2 in semen on semen quality. 
PCV2 DNA was detected in 30 of 903 semen samples and from 13
the study was not balanced by breed, PCV2 DNA was only detected in the Duroc and 
Landrace breeds. In another study, a host genetic difference among breeds suggests that 
 121
Landrace pigs may have a predisposition to PCV2-induced disease and lesions (171). Studies 
regarding PRRSV in swine produce similar observations to PCV2 infection, as PRRSV causes a 
persistent infection, and variability in the duration and presence PRRSV shed in semen exists 
among Landrace, Yorkshire, and Hampshire breeds (42). These observations suggest that breed 
susceptibility to PCV2-shedding in semen may exist. 
When considering boar age and time after entry into the boar stud, semen samples were 
less likely to be positive for PCV2 DNA with an increase in time. Boars ranged from 33.9 to 
149.3 weeks of age for the period of this study; however, no PCV2 positive semen sample was 
found in any boar after 71 weeks of age. A semen sample was 2.6 times more likely to be 
positive when collected from boars that were ≤52 weeks of age, and 3.0 times more likely to be 
positive when collected from boars that were ≤26 weeks from the time of entry into the stud 
main un
n, PCV2-shedding in semen occurred during a period of up to 27.3 weeks 
and sam
it. It appears that younger boars are more susceptible to shedding PCV2 in semen.  
Spermiograms were prepared with each semen sample submission for a subset of boars, 
and the ratio of live to dead sperm cells and specific morphological defects were determined, as a 
measure of semen quality. The effect of PCV2 semen status on semen quality, based on the 
proportion of live and morphologically normal cells was determined from 314 smears: 199 
smears from 10 PCV2-shedding boars; and 115 smears from eight boars that did not shed PCV2 
in semen. There was no association found between PCV2 DNA detection in semen and a 
reduction in semen quality. 
In conclusio
ples were more likely to be PCV2 positive when collected from younger boars. In 
addition to boar age, particular breeds may be more susceptible to PCV2-shedding in semen. 
PCV2-shedding in semen was sporadic in frequency and occurred in the absence of clinical 
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disease, as no PCVD was observed in the herd during this study. An elevated level of PCV2 in 
serum or tissues may not be necessary to result in the shedding of the virus in semen, as elevated 
levels of virus are typically associated with PCVD, and there was no observed clinical disease in 
the herd.   
Semen quality, measured as the proportion of live and morphologically normal cells, was 
not affected by the presence of PCV2 DNA in semen when PCV2-shedding and non-shedding 
boars were compared. However, it must be considered that boars infected naturally with PCV2 
may have sporadic and long-term shedding in semen, and testing for PCV2 in semen may be 
required for commercial studs supplying semen for artificial insemination. In a recent study, 
semen spiked with infectious PCV2 used for artificial insemination of sows resulted in viremia 
of the sow and PCV2 infection of piglets in utero (134). Future considerations regarding semen 
used in commercial swine facilities or for export may include a requirement for PCV2 testing in 
semen. 
l 
pigs (s
The third study was concerned with the development and validation of a novel 
quantitative PCR assay for PCV2. The hypothesis – a SYBR green real-time PCR assay can 
accurately quantify PCV2 in multiple tissues from PCVD-affected and nonaffected pigs – was 
supported by exploiting oligonucleotide primer binding sites conserved across 244 characterized 
PCV2 genomes. The assay targets the highly conserved ORF1 or Rep gene of PCV2 and was 
designed to target all genotypes (PCV2a/2b) (71) or genogroups (PCV2-G1/G2) (13) of PCV2.  
The assay was tested in multiple tissues from pigs: PCV2 naturally-infected conventiona
erum, buffy coat, feces, and multiple lymphoid (bronchial, mesenteric, and superficial 
inguinal lymph nodes, thymus, tonsil, ileal Peyer’s patches, and spleen) and non-lymphoid 
(myocardium, lung, kidney, liver, and gluteal muscle) tissues; PCV2 experimentally-infected and 
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non-infected gnotobiotic pigs (terminal serum and liver tissue); and plasmid-spiked PCV2-
negative serum, lung tissue, and feces. In addition, homogenized liver samples from the 
experimentally-infected gnotobiotes were tested by tissue culture and immunohistochemical 
staining, and expressed as TCID50.     
 Several quantitative assays were published at the time of the development of our assay 
(29;45;73;169;230); however, the majority of the assays target the less conserved capsid gene 
(ORF2). It is most desirable to choose target sequences that are strongly conserved, as the 
efficiency and ability to accurately quantify the target will be variably affected by mismatches 
between the oligonucleotide and the target sequence. The Rep gene (ORF1) is more conserved 
than the Cap gene (ORF2) (50) and the Rep gene is conserved among genotypes of PCV2. A 
more reliable quantitative PCR assay is an advantage of the assay described here. 
A plasmid (pl-492) and 10-fold dilution series was prepared for use in a standard curve to 
allow for the quantification of unknown samples by extrapolation. A dissociation curve was 
0 copies of plasmid per 25 
µL reac
performed after amplification by a gradual rise in temperature from 55ºC to 95ºC, and the 
fluorescence signal was measured every 0.5ºC.  A typical dissociation curve observed for PCV2 
infected tissues and the plasmid standards consisted of a single peak at 77.8ºC with no 
amplification in negative controls and negative samples (Figure 5.2).  
To determine the cutoff or detection limit of the assay, a known amount of plasmid (pl-
492) was spiked into the serum, lung tissue, and feces from a PCV2-negative pig. The linear 
portion of the standard curve was found to span 6.6 × 107 to 6.6 × 10
tion and was equivalent to 2.2 × 103 copies per mL. The detection limit corresponded to a 
threshold cycle (Ct) of 35.47 and was applied to each sample. By spiking known concentrations 
of plasmid at the beginning of the extraction process into the tissues from a PCV2-negative pig, 
 124
we were able to determine the effects of potential inhibitors and the extraction process (Figure 
5.3). Detection in serum was the most accurate until approaching the lower detection limit; 
however, in both lung and feces, the target copy number measured was less than the expected by 
approximately 2 logs. A 1:10 dilution of extracted lung tissue improved detection to within a log 
(Figure 5.4); however, dilution did not improve detection in feces. 
r the 
gnotob
quantification of PCV2 from a variety of tissues from naturally- and 
experim
To validate the assay, PCV2 naturally-infected wasting (n=3) and age-matched non-
wasting (n=3) pigs were selected and serum, buffy coat, feces, and 12 additional tissues were 
tested by the novel assay. Although the data set was small and represented only three pigs per 
group, the concentrations of PCV2 DNA were consistently higher in the wasting versus non-
wasting pigs (Table 5.2). In addition to samples from PCV2 naturally-infected conventional pigs, 
liver samples were collected and processed from PCV2 experimentally-infected and non-infected 
gnotobiotic pigs. PCV2 titers from the homogenized liver samples were determined fo
iotes based on TCID50 and immunohistochemical staining titration analysis (Figure 5.5). 
Increasing viral load from subclinical to severely PCVD-affected pigs was observed and found to 
be analogous to the observed results by the titration analysis. This suggests a relationship 
between the quantity of PCV2 DNA in tissue and the severity of PCVD, as reported by others 
(87;112;200). 
In conclusion, the assay developed in this study with a conserved target sequence 
performed efficiently in the 
entally-infected pigs. In testing these tissues, we confirmed the results of published 
studies where PCVD-affected pigs have increased PCV2 viral load in tissues when compared 
with non-affected pigs. Due to the conserved target of this assay, as PCV2 continues to evolve in 
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the field with a potential for new genotypes, this assay will out-perform existing or future assays 
with less conserved targets.  
The fourth study was concerned with the quantification of PCV2 in the feces of PCVD-
affected pigs compared with nonaffected pigs. The hypothesis – young pigs (<16 weeks of age) 
in a PC
is was used to test approximately 100 pooled fecal samples from each of the PCVD-
affected
VD-affected commercial herd shed significantly more PCV2 in their feces compared with 
pigs in a nonaffected commercial herd – was supported by quantitative PCR of approximately 
200 pooled fecal samples. Publications regarding PCV2 shed in feces have focused on 
quantification of the virus in pigs infected experimentally with PCV2 (32;68) or pigs naturally 
infected by the categories of subclinical, PMWS-affected, and nonaffected pigs (200). No 
previous reports have quantified PCV2 in feces by production stage in PCVD-affected and 
nonaffected herds.  
The quantitative real-time SYBR green assay developed in the third study presented in 
this thes
 and nonaffected herds. Each barn was sampled in a cross-sectional manner with 
approximately 50 fecal samples collected from each of the feeding and breeding herds. Fecal 
samples comprised multiple individual fecal samples from pigs housed in a pen with a variable 
number of pigs (Table 6.2) resulting in pooled samples. Each of 10 production stages was 
represented by 10 pooled samples: newly weaned; nursery; pregrower; grower; finisher; virgin 
gilt; bred gilt; lactating sow parity ≤2; lactating sow ≥3; and boar (Table 6.1).  
The observed median PCV2 shed in feces was higher in the PCVD-affected pigs for all 
production stages, with the exception of older pigs in the finisher, virgin gilt, and bred gilt stages. 
However, the amount of PCV2 shed was only significantly higher in the younger pigs in the 
PCVD-affected herd representing the newly weaned, nursery, and pregrower stages of 12 weeks 
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of age or younger. Of particular interest, the grower stage pigs (15 to 16 weeks of age) had 
significantly higher PCV2 in feces in the nonaffected herd. This suggests that PCVD-affected 
pigs may be exposed to PCV2 earlier or experience a higher infectious dose, or both.  
Exposure to PCV2 in the first three weeks of life would be primarily dependent on the 
sow an
affected herds. 
Compa
CV2 shed in feces have a 
higher 
d her shedding status in the farrowing crate. Our research found that the majority of 
lactating sows in the nonaffected healthy herd, in particular higher parity sows, did not have 
detectable levels of PCV2 in feces. In contrast, most lactating sows in the PCVD-affected herd 
shed PCV2 in feces (Figure 6.2). Sows shedding PCV2 in feces into the surrounding 
environment within the farrowing crate may expose piglets to the virus earlier and with a higher 
infectious dose. This early exposure in the farrowing crate would explain the increased PCV2 
shed in the feces of the younger pigs (from 3 to 12 weeks of age) in PCVD-
ratively, pigs in the nonaffected herd had increased PCV2-shedding three weeks later in 
the grower stage at 15 to 16 weeks of age. The observed delay in PCV2 fecal shedding in the 
nonaffected healthy herd would support the proposal that it is the mixing and remixing of pigs 
postweaning that contributes to and spreads PCV2 among the pigs, and not exposure to the virus 
from the sow in the farrowing crate.  
In addition, it must be considered that sows with increased P
systemic PCV2 viral load (200) and may be more likely to expose piglets to PCV2 via 
colostrum (206), or infect the fetus in utero (151;228). However, there have been no reports that 
correlate serum PCV2 viral load in the sow to infection of the piglet via colostrum or the fetus in 
utero.     
Lastly, maternal Ab protection provided to suckling piglets may be extremely variable 
among sows (149;182), but can be protective against PCVD and reduce the PCV2 viral load in 
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serum. This is evidenced by immunization of the sow prior to farrowing to increase serum 
PCV2-specific Ab, reduce serum PCV2 viral load (177), and protect young pigs from PCVD via 
passive immunity (100). The PCV2 immune status of the sows in this study was not known. 
Therefore, passive immunity to the piglets is another variable to consider when speculating as to 
why young pigs in the PCVD-affected herd succumbed to disease. 
In conclusion, more pigs in the nonaffected healthy herd, particularly lactating sows, did 
not shed PCV2 in feces. As a result, there may be an association between the presence of PCV2 
in the feces of lactating sows while in the farrowing crate with their piglets, increased quantity of 
the virus in the feces of pigs 3 to 12 weeks of age, and the morality associated with PCVD. 
Additional studies are warranted as these results from obtained from only one healthy and one 
PCVD-affected herd. 
The fifth and final study evolved from an opportunity provided by collaboration with the 
European Union sixth framework programme; Control of Porcine Circovirus Diseases (PCVDs): 
Towards Improved Food Quality and Safety. This group consisted of researchers and 
veterinarians from varied disciplines and countries focused on PCV2 research from the years 
2004-2008. This collaboration granted us access to ISCOM matrix technology and recombinant 
PCV2 protein for use in vaccination. During the four year research project, the PCVD status 
change
hypothesis – the use of a novel ISCOM based PCV2 VLP vaccine administered transdermally to 
d in parts of Canada, including a marked increase in PCVD mortality in Saskatchewan 
herds. The timing was ideal, as most of the producers in Saskatchewan were not using 
commercial PCV2 vaccines, yet, and we had a novel PCV2 vaccine candidate to test. 
This final study was concerned with determining the efficacy of a novel vaccine to 
prevent PCVD in pigs based on reduced mortality and four non-invasive outcome measures. The 
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one and three week old piglets can reduce PCVD-related mortality - was supported by 
vaccinating pigs in a PCVD-affected herd with the novel vaccine (n=27), or ISCOM matrix 
alone w
n conventional pigs was not previously reported. Several research studies 
have be
n of week one for 
fecal sa
ithout PCV2 VLP protein (n=27). To determine the efficacy of the vaccine, mortality and 
four non-invasive outcome measures were used: PCV2-specific Ab level in serum; PCV2 DNA 
concentration in serum and feces; and average daily gain (ADG). Taking into consideration the 
potential interference of maternally-derived Ab, it was imperative to learn if the vaccine could 
prime young pigs against PCV2 in the presence of PCV2 maternally-derived Ab and result in a 
reduction of mortality caused by PCVD in the affected herd.  
Prior to this study, several experimental PCV2 vaccine candidates had been reported to 
improve the immunity to PCV2 infection in swine (23;62;65). However, the use of ISCOM 
matrix technology i
en performed and published using ISCOMs and human rotavirus protein in gnotobiotic 
pig studies (74;99;163), but our study was the first to target PCV2 and test the matrix in 
conventional pigs. 
A collection schedule was made based on the results of our first study that determined the 
PCV2 Ab profile and viremia status in healthy conventional pigs infected naturally with PCV2 
(145). The observations made suggested to focus the collection of samples during the late 
nursery and pregrower stages from 7 to 13 weeks of age; therefore, samples were collected every 
two weeks during this period. Blood and rectal fecal samples (with the exceptio
mples) were collected at seven consecutive time points between 1 and 18 weeks of age 
from each of the 54 pigs in the study. Study pigs were weighed at 1 and 18 weeks of age to 
determine ADG over the study period. Pigs that were part of this study that either died or were 
euthanized because moribund were submitted for necropsy and histopathology to determine 
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cause of death or morbidity. Proportional mortality due to PCVD was calculated based on the 
results of the necropsy.  
Two previously described assays were used to measure the non-invasive outcomes and 
determ
 reduction in PCV2 replication and viral load. Additionally, 
these o
b that are protective against the development of PCVD. However, maternally-derived 
Ab can
ine the efficacy of the novel vaccine in this study. The quantitative PCR assay developed 
in the third study in this thesis was used to quantify PCV2 in the serum and feces of the 
vaccinated and control pigs. The previously described competitive ELISA used in the first two 
studies in this thesis was also applied in this last study to measure PCV2-specific Ab.  
PCV2 viral load in tissues has become a measure of the infection status or potential 
disease state of pigs in studies of PCV2 and PCVD. The PCV2 viral load or DNA concentration 
in tissues has been reported to be associated with the severity of PCVD in swine (87;112). 
Furthermore, in the fourth study described in this thesis, the quantification of PCV2 DNA in 
feces was found to be significantly higher in young pigs in a PCVD-affected herd when 
compared with a nonaffected herd (147). Additionally, PCV2 DNA concentration in serum, as 
measured by quantitative real-time PCR, is associated with PCVD severity (29;200). Therefore, 
PCV2 DNA concentration in serum and feces are appropriate matrices to measure vaccine 
efficacy, as they are correlated with a
utcome measures have the benefit of being non-invasive. Previously described studies 
show that quantitative PCR is a valuable tool to determine the efficacy of vaccination against 
PCV2, as evidenced by a reduction of the viral load in serum and tissues (69;110;176). 
An important consideration in determining vaccine efficacy is the production of PCV2-
specific A
 affect vaccine performance in young pigs (69); therefore, the use of ISCOM matrix 
technology was employed to attempt to circumvent this problem. ISCOMs have the ability to 
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prime animals against specific antigens in the presence maternally-derived Ab (84). We were 
able to determine the effects of maternally-derived Ab on our novel vaccine by categorizing our 
study pigs into either high (hiMDAb) or low maternally-derived Ab (loMDAb) groups within the 
vaccinated and control groups. 
In the analysis of this study, vaccine efficacy, based on the mortality and outcome 
measur
igh or low maternally-derived Ab. This was achieved by using the PCV2-
specific
ate factors 
against
es described, was made between vaccinated and control pigs. Additionally, the analysis 
went further by examining the effect of maternally-derived Ab status within and between the 
vaccinated and control pigs. Based on the high level of PCV2-specific maternally-derived Ab 
that were present in the one week old pigs in this study, analysis of the effects of the maternally-
derived Ab on the ability of the novel vaccine to prime the pigs were made by categorizing the 
pigs as having either h
 Ab median value among the study pigs as the cutoff point, as determined by competitive 
ELISA. Using this approach, the effect of the level of maternally-derived Ab on the ability of the 
novel vaccine to prime the young pigs could be determined. 
Using mortality as an outcome measure of vaccine efficacy was encouraging. Mortality 
attributed to PCVD was significantly higher in the control group (five pigs) compared with the 
vaccinated group (none of the pigs). An additional observation made was that all of the control 
pigs that died due to PCVD were categorized in the loMDAb group. This observation suggests 
that the vaccine was successful in priming and protecting pigs with loMDAb against a PCVD-
related death; however, control pigs with hiMDAb appeared to be protected by inn
 PCVD and did not require vaccination to prevent a PCVD-related death. This is 
supported by the observation that none of the control pigs with hiMDAb died due to PCVD.  
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PCV2-specific Ab level in serum was found to vary significantly among the groups 
immediately prior to the period when the study pigs experienced PCVD-related deaths. All 
deaths resulting from PCVD occurred between 9 and 11 weeks of age, and significantly higher 
levels of PCV2-specific Ab were observed in the vaccinated group at nine weeks of age. Upon 
further analysis, both hiMDAb and loMDAb groups within the vaccinated pigs at nine weeks of 
age had significantly higher PCV2-specific Ab when compared to the hiMDAb and loMDAb 
groups within the control pigs. Based on these observations, the vaccine successfully primed and 
elicited a PCV2-specific Ab response in the vaccinated pigs despite high levels of maternally-
derived
serum viral load in the hiMDAb group. Based on these observations, the 
vaccine
 PCV2-specific Ab in the hiMDAb group. 
PCV2 DNA concentration in serum demonstrated that the vaccine significantly reduced 
the PCV2 viral load in the vaccinated pigs during the period of PCVD-related deaths. However, 
when considering MDAb status within the vaccinated pigs, a significant difference in PCV2 
DNA concentration in serum was only observed in the loMDAb group and the vaccine did not 
appear to decrease 
 was not as efficient in the hiMDAb at stimulating a response to neutralize or prevent 
PCV2 replication. Since the previous outcome measure of PCV2-specific Ab was significantly 
higher in both the loMDAb and hiMDAb groups within the vaccinated pigs, it can be 
hypothesized that other immune factors contributing to the prevention of PCV2 replication, such 
as cell-mediated responses, were not as effectively stimulated or primed in the hiMDAb group.  
PCV2 DNA concentration in feces did not differ between the vaccinated and control pigs 
in this study, irrespective of MDAb status. Fecal swabs have been used by other researchers to 
determine the ability of a vaccine to reduce viral shedding, as a measure of vaccine efficacy (69). 
Additionally, our research from the fourth study described in this thesis found significant 
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differences in the amount of PCV2 shed in feces between a PCVD-affected and a nonaffected 
herd (147). However, the fecal extraction methodology between the fourth study and the vaccine 
efficacy
this study. 
Howev
edding in 
feces. A
 study differed, and this difference may have contributed to the negative outcome 
observed here. Alternatively, although the vaccine significantly reduced the PCV2 concentration 
in serum in the vaccinated pigs during the period of PCVD-related deaths, the vaccine did not 
reduce the amount of virus shed in feces. 
Average daily weight gain was not significantly different among the groups in 
er, pigs with hiMDAb had numerically higher ADG compared with loMDAb pigs within 
the vaccinated group. The difference in ADG between vaccinated and control pigs and among 
MDAb status groups may have been significant during the nursery and pregrower period when 
PCVD-related deaths occurred; however, weights were not taken at additional time points during 
the study. ADG is an important production measure and has been used to assist researchers in 
determining the benefits of vaccines against PCV2 (38). It appears that the vaccine in our study 
did not appreciably improve ADG; however, additional measurements during the study may 
have elucidated a benefit during the period of time when pigs succumbed to PCVD. 
In conclusion, the benefit of the novel ISCOM vaccine was most evident in the loMDAb 
VX, as these pigs were protected from a PCVD-related death that was otherwise experienced in 
the loMDAb CTRL. However, producers and veterinarians using a vaccine against PCV2 would 
expect a significant improvement in ADG, viral load in serum, and reduced viral sh
lthough the vaccine prevented a PCVD-related death in the highest risk population, the 
loMDAb group, modifications regarding the protein or ISCOM concentration, or PCV2 protein 
construction should be considered to potentially improve the vaccine’s efficacy. 
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Upon completion of the five studies that comprise this thesis, a general observation or 
conclusion can be made. Molecular diagnostic assays, in particular quantitative assays, are 
extremely useful tools that have evolved over the last 10 years in the study of PCV2 infection 
and PCVD. All of the studies presented here share this diagnostic tool and allowed us to discover 
previou
around the world, this is not a virus 
that w
rch 
articles revealing details of PCV2 and PCVD have been published over the last decade. 
sly unknown information regarding PCV2 in both healthy and PCVD-affected pigs. The 
quantification of PCV2 in serum and tissues has a direct relationship to the PCVD status of 
affected pigs (87;112;200). The ability to determine the PCV2 status of a herd that may progress 
to increased losses due to PCVD is an important element in the prevention of disease. The 
importance of non-invasive screening tools to ascertain herd health will give producers and 
veterinarians the information needed to decide on the implementation of vaccines against PCV2 
or to make other changes in the management of their herd. Additionally, with the use of 
quantitative molecular assays, vaccine efficacy can continue to be tested and improved upon. 
Vaccination programs have proven to be effective against the development of PCVD; 
however, due to the ubiquitous PCV2 infection of pig herds 
ill be eradicated. Rather, research will continue to discover answers regarding the 
transmission and pathogenesis of the virus, and vaccine use will reduce pig losses due to the 
development of PCVD. PCV2 infection and pathogenesis is complex. Producers and 
veterinarians can not become complacent regarding the threat of PCV2 and PCVD, as evidenced 
by the resurgence of severe disease in Canada in the last five years (71). Most aspects of PCV2 
infection including the cofactors/triggers, transmission, effect of nutrition, sites of replication, 
pathogenesis, interaction with host immune response, role of porcine genetics, molecular 
processes of replication, and potential control of PCVD have been studied. Hundreds of resea
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Howev
Dogs look up to us. Cats look down on us. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
er, we remain decades away from a complete understanding of the complexity of PCV2 
infection and pathogenesis, and the development of PCVD. 
 
 
I like pigs. 
Pigs treat us as equals. 
Sir Winston Churchill 
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